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TARGETING SINGLE-WALLED CARBON NANOTUBES FOR THE 
TREATMENT OF BREAST CANCER USING PHOTOTHERMAL 
THERAPY 
 
LUÍS FILIPE FERREIRA NEVES 
 
ABSTRACT 
 
To develop a therapeutic system with cancer cell selectivity, the present study 
evaluated a possible specific and localized tumor treatment. Phosphatidylserine (PS) 
exposure on the external face of the cell membrane is almost completely exclusive to 
cancer cells and endothelial cells in the tumor vasculature. The human protein annexin 
V is known to have strong calcium-dependent binding to anionic phospholipids such as 
PS. This protein was studied for targeting single-walled carbon nanotubes (SWNTs) to 
the vasculature of breast tumors. 
The synthesis of the protein annexin V, by a pET vector in Escherichia coli, 
constitutes the first phase of this study. Recombinant annexin V was purified from the 
cell lysate supernatant by immobilized metal affinity chromatography. The overall 
production of purified annexin V protein was 50 mg/L.  
The binding ability of the protein annexin V was evaluated by determining the 
dissociation constant when incubated with proliferating human endothelial cells in vitro. 
The dissociation constant, Kd, was measured to be 0.8 nM, indicating relatively strong 
binding. This value of Kd is within the range reported in the literature. 
xx 
Single-walled carbon nanotubes (SWNTs) were functionalized with annexin V 
using two intermediate linkers (containing FMOC and DSPE) resulting in stable 
suspensions. The SWNT and protein concentrations were 202 mg/L and 515 mg/L, 
respectively, using the linker with DSPE (average of nine preparations). The 
conjugation method that used the DSPE-PEG-maleimide linker allowed to successfully 
conjugate the SWNTs with final concentrations approximately five times higher than 
the linker containing FMOC. The conjugation method used has a non-covalent nature, 
and therefore the optical properties of the nanotubes were preserved. 
The conjugate was also visually observed using atomic force microscopy 
(AFM), allowing to verify the presence of the protein annexin V on the surface of the 
nanotubes, with an height ranging between 2.5 to 5.0 nm. Confocal microscopy was 
used to prove the binding of the conjugates to human endothelial cells grown in vitro.  
Proliferating endothelial cells were used to determine the optimal near-infrared 
(NIR) laser irradiation settings (energy density = 200 J/cm2), which would not induce 
cell cytotoxicity from the laser itself. A 2 hour incubation with the conjugate followed 
by a washing step and NIR irradiation (wavelength = 980 nm, power = 1 W/cm2, time = 
200 seconds) was enough to induce significant cell death (≈ 55 %), without significant 
damage to the control samples. 
Administration of the same conjugates i.v. in Balb/cJ female mice resulted in 
detectable accumulation of the SWNTs in the tumor tissues, with minimal retention in 
the kidneys 24 hours post-administration. A dosage of 0.82 mg/kg of SWNTs 
administered i.v. and followed one day later by a NIR irradiation (wavelength = 980 
nm, power = 1 W/cm2, time = 175 seconds) led to complete disappearance of implanted 
xxi 
4T1 mouse mammary tumors for the majority of the animals from the treatment groups, 
within a few days. The combination of the photothermal therapy with a low dosage (50 
mg/kg) of the immunoadjuvant cyclophosphamide, given 2 days before NIR irradiation, 
was also evaluated; this resulted in increased survival. Histological findings revealed 
the complete obliteration of the tumors treated from the original site, with complete 
regeneration of the skin epithelial layer and absence of cancer cells. 
In conclusion, this research was successful in demonstrating that SWNTs could 
be targeted to the tumor vasculature in vivo and then could be heated by NIR irradiation 
to completely kill mouse mammary tumors implanted in immune-competent mice. 
There is evidence that the co-administration of the immunostimulant cyclophosphamide 
caused increased survival of the mice. It is recommended that future work be directed to 
exploring methods to increase the concentration of the SWNT-annexin V conjugate in 
the tumor and to evaluate the co-administration of other immunostimulants, either alone 
or in combination. 
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CHAPTER I 
 
 
 
INTRODUCTION 
 
 
2 
1. Cancer 
 Cancer can be defined as a group of diseases characterized by an uncontrolled 
cell division, invading the adjacent or distant tissues (metastasis) [2]. Being considered 
the world’s most complex disease process, it is related to 100 or more single diseases 
[3]. There are several possible environmental factors that can induce cancer, such as 
exposure to radiation, hereditary factors, viruses, smoke, alcohol, dietetic habits, 
contributing to approximately 80 % of cancers [3, 4]. Cancer can exhibit different 
symptoms, although it can be asymptomatic until advanced stages. Risk factors include 
geography, ethnicity, dietary habits, age, and hereditary genes that increase the 
predisposition for cancer. 
 Based on the statistics, the frequency of a specific cancer may depend on gender 
[5]. According to the American Cancer Society 1,639,000 new cancer cases are 
expected to be diagnosed in 2012, excluding carcinoma in situ (noninvasive cancer) of 
any site (except urinary bladder) and basal and squamous cell skin cancers. Being 
considered the second leading cause of death in the U. S., statistics confirm that there 
are more than 1,500 persons dying per day as victims of cancer [6]. The most common 
types of cancer in the U.S. are the prostate cancer and breast cancer (Figure 1). 
 
 
  
 
Figure 1: Leading sites of new cancer cases and deaths. *Excludes basal and squamous cell skin cancers and in situ carcinoma except 
urinary bladder [6].
             3 
4 
 
In order to perform cancer treatment, there is an inherent difficulty in 
distinguishing malignant cells from normal cells. Both of them share the same origin, 
which helps explain the fact that cancer cells are not significantly recognized by the 
immune system. 
Generally, the treatment results from the combination of different therapeutic 
techniques, such as surgery and chemotherapy [2]. According to some studies, these 
techniques can be very efficient; however, they carry associated-side effects for the 
patient [2]. A specific case is chemotherapy, based on the introduction of chemical 
substances in the bloodstream in order to control cell processes. The side effects 
associated with this therapy are related to the collateral destruction of normal cells [2]. 
When manifested, examples of these effects are anxiety, anemia and fatigue due to the 
red blood cells decreasing, diminution of white cells and platelets, renal perturbations, 
digestive system alterations and loss of appetite, and increase in weight, alopecia, in 
addition to other symptoms. 
Because of the need for an improved system to treat cancer, the general goal of 
this study is to eradicate all cancer cells in the body, while not affecting healthy cells. 
By specifically targeting cancer cells, the side effects associated with the conventional 
therapeutic methods are avoided. The development of a system with intra-venous 
administration allows a global spread through the entire body, eliminating the 
conventional problems of localization and treatment of metastatic regions [2]. In this 
study, the protein annexin V which has PS-binding properties is used as targeting 
moiety. It is a very important marker for cancer cells, since cancer cells and endothelial 
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cells in the tumor vasculature expose PS on the external leaflet of the plasma 
membrane. 
 
2. Annexins 
The annexins are a group of proteins with similar properties [7, 8] that were 
initially named by Geisow [7, 9].  This name is derived from the Greek annex meaning 
“bring/hold together” [10]. The annexins are different proteins, with a common C-
terminus attached to an amino acid repeated domain, although presenting a unique N-
terminal domain [7, 8, 10, 11]. 
Discovered by Pazoles, Creutz and Polland approximately 34 years ago at the 
National Institute of Health [12], the annexins are a protein family comprised of 12 
different proteins with a common important characteristic – the affinity binding of a 
phospholipid to Ca2+ [7, 8, 10, 11, 13-15]. These calcium-dependent membrane binding 
proteins [8, 16] are involved in the membrane-related processes of exocytosis [11], 
adhesion, fusion and remodeling of the plasma membrane [16, 17], phospholipase 
regulation, cytoskeletal organization [11], cell growth, and transformation [8]. Adhesion 
mechanics, membrane traffic [8, 11, 15], signal transduction [11] and/or developmental 
process are other proposed functions [18]. 
 
2.1. Annexin V 
Annexin V, a monomeric protein [19], has a structure with four homologous 
repeated domains. It is a non-glycosylated protein, although it has potential O-
glycosylation sites (without N-linked glycosylation sites)  [20], and it has a single 
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cysteine four residues from the C-terminus. In vitro studies show that annexin V reveals 
an ion channel activity, binding in a calcium-dependent manner to acidic phospholipids 
(e.g., phosphatidylserine [12, 21-23]). 
The annexin V molecule is believed to have three Ca2+ binding sites (Ca1 to 
Ca3) [24], situated at the convex face of the molecule as possible phospholipid binding 
sites [15], which have structural similarity to the calcium site present on phospholipase 
A2. Huber et al., concluded that membrane-bound and soluble annexin V present very 
similar structures, since the membrane-anchoring region is located on the convex face 
[24]. It has been proposed that it is involved in exocytosis [12, 15, 25], anti-coagulation 
[10, 25, 26], anti-inflammation [25], anti-thrombotic processes [10, 16], and cell 
differentiation or replication [15, 25]. 
Annexin V has a single polypeptide chain that is 320 amino acids long 
(Appendix B) [15, 27] (including the first methionine) with an evaluated molecular 
mass of 35,935 Da [27] and dimension of 64 x 40 x 30 Å3 [16], folded into four 
domains of similar structure arranged in an almost planar cyclic array [10, 24]. Each 
domain is composed of five α-helices with an approximately 18 Å diameter (Figure 2).  
 
Figure 2: Homo sapiens annexin V crystal structure. The ribbon drawing illustrates the 
highly α-helical folding of the protein core that forms a slightly curved disk. Different 
colors were chosen to highlight the four annexin repeats that are given in green (repeat 
7 
 
I), blue (repeat II), red (repeat III), and violet/cyan (repeat IV). The NH2-terminal 
domain appears unstructured and extends along the concave side of the molecule 
(green). The high and low Ca2+ forms are shown in a superposition revealing the 
conformational change in repeat III, which leads to an exposure of Trp-187 (violet for 
the low and cyan for the high Ca2+ form). Bound Ca2+ atoms are depicted as yellow 
spheres [10]. 
 
Annexin V is a member of calcium-dependent phospholipid binding proteins 
[13, 22, 28] with a high binding affinity (Kd = 0.5-7 nM - dissociation constant) [26] to 
PS-containing phospholipid bilayer [26, 29-33]. According to its intrinsic properties, 
annexin V can be used as an apoptotic cell marker. When combined with a radioisotope 
or fluorochrome [28], it constitutes a powerful imaging system [28, 33, 34]. Annexin V 
constitutes the basis for a sensitive flow cytometric assay for cells undergoing apoptosis 
[21, 34]. Diseases and mechanisms, such as heart failure, aplastic anemia, or transplant 
rejection, involve high apoptosis occurrence; therefore, it is possible to image them 
using annexin V [21]. In this study, we used E. coli in order to express annexin V, since 
in that system annexin V can be very easily expressed in a soluble form with the great 
advantage of non-fusion with another protein [15]. 
 
3. Phosphatidylserine 
Phospholipids are a major structural component of the cell membrane and can be 
involved with some cancer signaling [17]. Phosphatidylserine (PS) is an anionic 
phospholipid that, in normal cells, is exclusively present and tightly segregated in the 
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internal leaflet of the plasmatic membrane [11, 35-40]; i.e., it presents an asymmetric 
and heterogeneous distribution [41, 42] (Figure 3). That characteristic asymmetry [35] 
is maintained by a particular enzyme – aminophospholipid translocase – that transports 
PS to the cytoplasm [35, 41, 43, 44]. When the cell is under certain conditions, the PS is 
transported from the cytoplasm to the external leaflet of the membrane [28], by 
activation of a Ca2+-dependent enzyme scramblase (responsible for the bi-directional 
lipids transport) or by inhibition of the aminophospholipid translocase [41, 43]. 
 
 
 
 
 
 
 
 
 
(a) (b) (c) 
 
Figure 3: (a) Molecular organization of phosphatidylserine (PS). (b) PS is 
preferentially distributed in the inner leaflet of the cell membrane in normal cells. (c) PS 
is externalized on the cell surface of endothelial cells in tumor vasculature [45]. 
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When normal cells are exposed to some stress conditions, they undergo 
oxidative stress that can be caused by the presence of cancer cells. It is known that 
hypoxia/reoxygenation conditions and the presence of activating cytokines [46], 
leukocytes and metabolites [47] are preponderant factors of cell stress. This specific 
stage induces the production of reactive oxygen species. The ensuing oxidation of 
membrane phospholipids and the generation of calcium fluxes [35] will also provoke 
the inhibition of aminophospholipid translocase and/or activation of PS exporters [48]. 
The exposure of the cells to reactive oxygen species can contribute to the 
activation of several factors that promote the occurrence of apoptosis [4, 49]. Therefore, 
it is possible to conclude that the PS can be considered abundant, accessible [47] and a 
marker of apoptosis [36, 49], being a facilitator of macrophage phagocytosis of 
apoptosis cells [28, 33, 42, 47]. Research has proven that when the cell is exposed to 
necrosis factors, the PS is also exposed on the external leaflet of the plasma membrane 
[36]. PS plays an important role in aging, blood coagulation, cell-cell recognition, and 
apoptosis [34, 41, 49]. 
The evidence that endothelial cells present in the tumor vasculature externalize 
PS [36, 46] is an important and basic idea to the development of this study. The notion 
that exclusivity, i.e. the exposure of PS, does not occur in normal cells contribute to the 
development of an efficient and localized therapeutic and imaging system [46] that 
allows for precise tumor localization. 
In mammalian cells, a higher concentration of PS–an excellent marker of tumor 
vasculature [36, 46]–is observed in the plasma membrane in comparison with the other 
cell organelles, also being the most abundant lipid of the plasma membrane [36]. The 
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increasing platelet procoagulant response verified in certain tumors is considered one 
contributing factor in the translocation of PS to the external leaflet of the membrane 
[50-52]. The presence of thrombin [35, 36, 53], viral infection [54], hyperlipidemia 
[55], inflammatory cytokines [36], hydrogen peroxide [35], and docetaxel [36] 
contacting endothelial cells promotes PS externalization. Cell degranulation [56], cell 
aging [57], malignant transformation, cell activation [35, 36], cell migration [58], cell 
injury [35], programmed cell death [23, 49, 59, 60], intracellular fusion of trophoblasts 
[61] and myoblasts [62] and activation of platelets [10, 50] are other factors associated 
with the induction of PS externalization. These stimuli when combined may amplify the 
PS externalization [35]. In some cases, spontaneous appearance of PS can also occur in 
malignant cells in the absence of cell injury or exogenous activators [63, 64]. 
There are several characteristics pertaining to PS in cells: they are abundant (PS 
is present at more than 106 molecules per cell); they are on the luminal surface of tumor 
endothelium, which can be directly accessible for binding by vascular targeting agents 
in the blood; they are present in a significant percentage of tumor endothelial cells in 
diverse solid tumors; and they appear to be absent from endothelium in all of the normal 
tissues [35]. In vivo studies have shown that the exposure of PS occurs on tumor 
endothelial cells in various solid tumors, including metastatic tumors and drug-resistant 
tumors, and are on the luminal side of tumor endothelium, which is freely accessible for 
binding by targeted drugs [2, 65]. 
A detailed analysis [66] has shown that tumor vessels present structure 
deficiencies showing thin, leaky and tortuous walls, irregular shape, dilatation [2], 
insufficient supportive pericytes, and can have dead ends [2]. This anomaly increases 
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the sensitivity to radiotherapy, vascular targeting agents (VTA), and chemotherapeutic 
drugs [2]. Another important aspect is that endothelial cells present in normal 
vasculature are quiescent and nondividing, whereas tumor vascular endothelial cells are 
active and proliferative [4]. 
Because of annexin V’s high affinity and specificity for phospholipids 
(particularly PS) [36], it can be used for targeting or the imaging of tumor blood vessels 
(target molecule) [49]. More sophisticated systems include the possibility of annexin V 
being used to deliver a radionuclide, a cytotoxic drug [2] or coagulant to tumor vessels 
[35]. This affinity property permitted the use of annexin V to image activated platelets 
[31] in thrombi apoptotic cells in cardiac allografts undergoing rejection, 
cyclophosphamide-treated lymphomas, and anti-Fas antibody-treated livers in rodents 
[67]. 
 
4. Single Walled Carbon Nanotubes (SWNTs) 
In order for the annexin V-PS in vivo binding to be possible, it is necessary to 
use an efficient carrier that, when injected in the bloodstream, will not cause significant 
side effects. Single walled carbon nanotubes (SWNTs) are a relatively new type of 
nanoparticles that are explored in this research for targeting by annexin V to the tumor 
vasculature. SWNTs have very high absorption of heat when they are exposed to near-
infrared light at a specific wavelength, and this property can be used in a photothermal 
treatment of tumors.  
Because of their high hydrophilicity, water-solubilized nanotubes do not present 
toxicity, even at high concentrations. In vivo biodistribution and tumor targeting studies, 
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using animals, showed that there is a specific elimination profile for SWNTs – being 
eliminated in the urine with a small accumulation at the liver and reticuloendothelial 
system (RES) [68]. 
Carbon nanotubes present a very defined structure, showing a cylindrical 
structure with dimensions that can vary between several hundred nanometers to a few 
centimeters (length) [69] and 0.4-2 nm (diameter) for SWNTs [70]. In the present study, 
(6,5) nanotubes were used with diameter of 0.9 nm [71]. Carbon nanotubes have several 
optical, mechanical, electronic and thermal properties of interest [72, 73] such as high 
electrical conductivity, high aspect ratio (length is approximately equal to 1000 times 
the diameter), low thermal expansion coefficient, high thermal conductivity, very high 
tensile strength, high elasticity (approximately 18 % to failure), good electron field 
emitters and high flexibility (can be bent considerably without damage) [74, 75]. The 
high aspect ratio is an important property, since it is possible to incorporate several 
types of molecules with different sizes from small molecules to proteins [76].  
Those properties of the nanotubes constitute a promising field with potential 
technological applications [77]. SWNTs are “rolled-up” artificial nanostructures [72] of 
a unique layer of graphene [70, 72]. Carbon nanotubes are cylindrical carbon allotrope 
molecules that can be used in several different fields of study (e.g., nano-electronics, 
optics, materials applications, biological and biomedical systems [70] and biosensor and 
bioreactor systems).  
Biochemical sensors, diagnostic imaging contrast agents, targeted 
chemotherapeutics, in vitro cell markers, and photoablative therapy agents [72] are 
examples of SWNT biomedical applications. The use of nanotubes in biotechnology is 
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possible since specific molecules, such as enzymes or proteins, can be immobilized on 
the surface or in the hollow cavity of nanotubes [70, 73]. The fact that nanotubes 
present two distinct surfaces (inner and outer surface) shows they can be functionalized, 
presenting different properties from the inner surface to the outer surface [73, 76]. 
Nanotube-protein conjugates can afterward be integrated into biological systems. 
Generally, because of their properties, nanotubes constitute an excellent mean of 
transportation in vivo, allowing the delivery of a specific compound (e.g., drugs, 
peptides, nucleic acids [73]) into a concrete region, including the possibility of 
performing gene and protein therapy [77]. The delivery of genetic material into living 
cells–transfection [76]–is another example of a nanotube application. Antigen 
recognition, DNA hybridization, enzyme-catalyzed reaction [70], use as vehicle for 
enzyme encapsulation, DNA transfection, biosensors and drug delivery [73, 76] are 
some examples of how nanotubes can be used. 
 Different types of nanotube functionalization are available, being possible to 
adjust the nanotubes to a specific desired property. For example, the functionalization 
with PEG (PEGylation) allows nanotube solubilization, increasing the biocompatibility 
[68, 73, 76] that is an important factor to perform some biological studies [70, 77]. 
Generally, the nanotube suspension is required to be highly water-soluble, presenting a 
dark-colored aqueous suspension [78]. High bioavailability, biocompatibility, 
nontoxicity [79] and target ability are important properties present in functionalized 
nanotubes. 
 It is known that biological systems have a high transparency in the near-infrared 
(NIR) light window (700-1100 nm) [73, 79]. The characteristic of strong optical 
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absorbance of SWNTs in this wavelength range–a property related with the electronic 
band structures of nanotubes–can be evaluated by analysis of an S11 absorption 
spectrum. The spectrum of (6,5) SWNTs shows the presence of a characteristic peak at 
980 nm [80] (Figure 4).  
 
Figure 4: Fitting of the S11 absorption spectrum for SWNT sample synthesized on 
CoMo/SiO2 at 750 ºC [80]. The nanotube chirality is shown on the top of each 
absorption peak. The (6,5) SWNTs have an absorption peak at 980 nm. 
 
The strong optical absorbance makes it possible to perform optical stimulation 
of the nanotubes, when injected into the organism [79]. When the SWNTs are bound to 
specific receptors in vivo, the continuous irradiation with NIR light on a specific region 
can promote cell death because of a local temperature increase [73, 79]. However, the 
cells not expressing those receptors will not be injured. 
Generally, the nanotubes produced are typically interassociated, forming 
bundles showing an extremely low solubility in the presence of organic solvents or 
water [81]. In order to solve this particular problem (dispersion and solubility of single 
walled carbon nanotubes), different methods have been proposed such as high-shear-
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flow mixing, milling, and ultrasonication [81] combined with the use of dispersing 
agents and surfactants [81]. 
 Chemical functionalization is another method that demonstrates a high potential 
of use. This method can involve covalent or noncovalent bindings. The high reactivity 
of the carbon atoms present at the ends of the nanotube structure allows the performing 
of several reactions that seek the establishment of a covalent-binding type. However, 
this method is not reliable since just a small fraction of the carbon atoms in the 
nanotube structure becomes functionalized. 
 Side-wall covalent functionalization is another available covalent attachment 
method that provides a high carbon atom functionality. This method gives alterations in 
the optical properties of the nanotubes (loss of optical absorption and 
photoluminescence) caused by changes induced in the graphene original structure, 
constituting a severe disadvantage [81]. 
Adsorption of the protein and adsorption of an inert macromolecule followed by 
covalent attachment of the protein to the macromolecule are possible methods to form a 
protein-SWNT complex [81]. The adsorption of biomolecules to SWNTs does not 
induce any significant change in the intrinsic properties of the SWNTs, with the UV-
Vis-NIR absorption of the SWNT´s property conserved [79]. Figure 5 shows a 
schematic diagram of the mode of attachment of a phospholipid to the surface of the 
NTs.  
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Figure 5: A single walled carbon nanotube wrapped with PEG. PEG molecules have a 
radioisotope molecule attached to them and others have the RGD peptide [73]. 
 
 The use of some dispersing agents and surfactants [81] allows for a good 
distribution and individually nanotube separation from each other. The use of a low 
concentration of sodium dodecyl sulfate [82], sodium cholate [83], or low-viscosity 
sodium carboxymethylcellulose [80] as dispersants is encouraged because they are 
considered good nanotube dispersants.   
 
5. Photothermal Ablation for Cancer Therapeutics 
During the last few years, the number of scientific publications published 
involving the usage of SWNTs combined with a NIR laser for cancer therapeutic 
applications has greatly increased. The first successful attempt to eradicate cancer cells 
using nanotubes combined with a photothermal treatment was reported by Kam et al. in 
2005 for an in vitro study [79]. The SWNTs were non-covalently attached to targeting 
moieties which bound to cells of interest. After NIR irradiation, cell death was achieved 
for the treatment groups using an energy density of 168 J/cm2. Shao et al. [84] 
performed another in vitro study using breast cancer cells that were targeted by mAbs 
attached to SWNTs. NT internalization was verified and after NIR irradiation at 144 
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J/cm2 there was a significant cell killing ratio. Chakravarty et al. [85] published a 
research article where SWNTs were incubated in vitro with lymphoma cells causing 
thermal ablation by photothermal therapy, using an energy density of 2,100 J/cm2. 
Other groups have also evaluated this therapeutic approach using in vitro models and 
different cell lines such as neuroblastoma cells (MWNTs) [86], breast cancer cells 
(SWNTs) [87] and human prostate cancer (PC3) and murine renal carcinoma (RENCA) 
cells [88]. 
In 2009, Zhou et al. [89] published a study that used the same type of carbon 
NTs used by our group–the (6,5) CoMoCAT SWNTs. The nanostructures were 
functionalized with folic acid, binding specifically to the surface of certain tumor 
markers that express folate receptors. The irradiation of those conjugates was done 
using a NIR light set at 980 nm. Murine mammary tumor line EMT6 cells were used for 
both in vivo and in vitro studies. The irradiation profile used contributed to the 
eradication of a large portion of the cells either in vivo or in vitro. The injection of the 
conjugates was intratumoral. Moon et al. also used PEGylated SWNTs to achieve 
complete eradication of tumors over a 6 month period on mouth carcinoma xenografts 
(nude mice) [90]. The SWNT conjugates were administered through intratumoral 
injections which led to a particular accumulation of those structures in the surrounding 
skin and muscular tissue. Complete tumor eradication was reported to occur by 20 days 
after the NIR irradiation. The treatment group (SWNTs + NIR) did not reveal toxicity, 
strange behavior and was mainly in a good and healthy condition over 6 months. There 
was no tumor reoccurrence on this group. The control group that was irradiated with 
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NIR light but did not receive SWNTs had an identical behavior when compared with 
the untreated group. 
A later study by Robinson et al. published in 2010 [91] showed in vivo complete 
tumor eradication for more than 6 months using SWNTs conjugated with PEGylated 
phospholipids. The conjugates were administered intravenously.  The group reports that 
they used the lowest power level to date (P = 0.6 W/cm2, E = 180 J/cm2) and a dosage 
of 3.6 mg/kg. On this study the imaging of the NTs was also studied due to the optical 
properties inherent to the NTs in the NIR range. 
Other studies also used carbon nanotubes to achieve tumor obliteration in vivo 
using intratumoral injections [92, 93]. In 2011, Liu et al. [94] published a successful 
study where the tumors were treated using an i.v. administration of the conjugates. The 
SWNTs used were PEGylated in order to achieve a relative long blood circulation half-
life (12 h) with a high uptake in the tumor. The irradiation was conducted at 808 nm for 
5 minutes using a power density of 1 W/cm2 (Energy density = 300 J/cm2). One day 
after irradiation the tumors disappeared for 5 out of 7 animals in the treatment group, 
with the generation of black scars on the irradiated area. Three of those tumors did not 
regrow during the 2 weeks after the treatment. On the other 2 animals the tumors 
restarted growing approximately a week after irradiation. Two out of seven animals did 
not see a tumor eradication and the irradiation led to partial burning and consequent 
slower growth rate. 
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6. Mechanisms of Attachment of Annexin V to SWNTs using Intermediate Linkers 
The use of intermediate linkers to couple proteins to the surface of SWNTs is a 
common approach [95]. In order to isolate the NTs, they are suspended in SDS (Figure 
6)-which is a surfactant and minimizes the interactions between the tubes. The linkers-
FMOC-NH-PEG-NHS (Figure 7) and DSPE-PEG-Maleimide (Figure 8) have a 
hydrophobic group which has the ability to interact with the surface of the NTs due to 
the establishment of π-π interactions (strong and irreversible binding) [96, 97]. The 
intermediate poly-ethylene glycol molecule (M.W. = 3,400 Da) will contribute to 
increase the solubility of the suspension as well as act as a spacer between the surface of 
the nanotubes and the protein anchorage point (succinimide group). The attachment of 
the protein to the linker occurs at the other extremity of the linker where there is a 
succinimide group (FMOC linker) or a maleimide (DSPE linker). During a dialysis step 
the NHS group undergoes hydrolysis and gets converted into a carboxylic group. This 
group is then used to react with the N-terminal of the protein through a carbodiimide 
reaction. The attachment of the DSPE linker to the protein occurs by having a Michael 
addition, where there is the reaction of a maleimide group with a cysteine (present on 
the annexin V) (Figure 9).  
 
 
Figure 6: SDS structure [98]. 
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Figure 7: FMOC-NH-PEG-NHS linker structure [99]. 
 
 
Figure 8: Chemical structure of the DSPE-PEG-Maleimide linker [1]. 
 
Figure 9: Chemical reaction between a maleimide group and a cysteine [100]. 
 
7. Tumoral Morphology and Implications for the Current Therapies 
This study aims to overcome the known limitations of the conventional therapies 
by enhancing the degree of cell death while minimizing the collateral damage of 
adjacent and viable tissues. In order to evaluate the ability of the photothermal therapy 
to cause cell thermal ablation, it was required to perform some in vitro studies where 
human endothelial cells were used. This particular cell type was chosen in order to 
evaluate and mimic the environment and the conditions present at the in vivo level. 
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The vascularization of the tumors is of extremely importance due to the 
necessity of an appropriate nutrient and oxygen supply and removal of waste 
metabolites. Angiogenesis plays an extremely important and crucial role on the 
development of the tumors. For smaller tumors that are under 1 to 2 mm3 there is no 
vascularization present since there is diffusion of the oxygen to those cells [101, 102]. 
However, when the tumors start becoming larger, there is the occurrence of cellular 
hypoxia in the center of the tumor [101]. This condition results in triggering the process 
of angiogenesis which will lead to the formation of new vessels. Since, tumors result 
from the fast and decontrolled replication of the cells, the vasculature that is created and 
irrigates the tumors is generally abnormal. Those vessels are not allowed to form 
completely, and therefore the vasculature is usually characterized as irregular and leaky 
[102]. The existence of large gaps and absence of gap junctions between the endothelial 
cells explains the leaky nature. This phenomenon is known by the scientific community, 
and it is commonly used as a way to allow the migration of targeting moieties and/or 
drugs into the cancer cells. The firm and tight junctions between the endothelial cells on 
the normal vasculature do not allow relatively large molecules to penetrate into the 
surrounding tissues. Therefore, we can design conjugates that will be injected into the 
bloodstream, will travel through the entire organism, and then will selectively bind to 
the surface of the abnormal endothelial cells but also to the cancer cells that are 
surrounded by the vasculature in some extent.  
Different oncological therapies aim to interrupt the angiogenesis requested by 
the tumor cells [103]. Also the irregular vasculature is responsible for the generation of 
enhanced permeation retention effect [104], which is characterized by the lack of an 
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effective lymphatic drainage. This effect will cause dramatic changes in the fluid 
transport dynamics at the tumoral level.  
 
8. In vivo Studies 
In order to test the ablation of tumors using SWNTs and photothermal therapy in 
vivo, it was required to perform some animal studies using BALB/cJ mice (Figure 10), 
which have a fully functional immune system. The use of immune-competent mice is a 
much more realistic test of cancer therapy compared to using mice with an impaired 
immune system, such as athymic mice or SCID (severe combined immune deficiency). 
This particular strain has a low mammary tumor incidence; however the mice generally 
develop some tumors when they become older, such as primary lung tumors, reticular 
neoplasms and renal tumors [105]. These animals belong to an inbred strain, which 
means that the individuals across the strain are almost genetically identical. The weight 
distribution across this particular strain is illustrated on the Figure 11. 
 
 
Figure 10: Picture of a BALB/cJ mouse [106]. 
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Figure 11: Body weight information for the JAX® mice strain BALB/cJ [107]. 
 
Since we were interested in studying the efficacy of this therapy for the 
treatment of tumors, it was decided to use a cell line that mimics the human breast 
cancer. For that, the 4T1 metastatic breast cancer model (Appendix M) was chosen due 
to the fact that these cells grow fast and when inoculated in vivo allow for the formation 
of tumors that will resemble the human breast cancer. This particular cell line was 
derived from a BALB/c mouse mammary tumor which developed spontaneously [108]. 
This cell line can be injected orthotopically into the mammary fat pad of the animal or 
subcutaneously. The cells can also be injected through the bloodstream. The occurrence 
of metastases in a short time frame is characteristic of this particular cell line, and 
within few weeks there is the appearance of metastases in the lungs, bone, liver and 
brain. The metastases found on the lungs can easily be visualized at the naked eye after 
careful dissection of those organs. They occur as nodules that can be quantitatively 
determined in order to evaluate the degree of metastasis. The similarity between this 
model and the human disease defines this model as an excellent candidate to study the 
metastatic development of breast tumors in humans. The use of a mouse cell line gives 
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the ability to overcome some of the limitations inherent to the usage of human tumor 
cell lines which are known to have a slow growth rate and deficient metastasis ability. 
 
9. Immunostimulation Therapy of Cancer using Cyclophosphamide 
Cyclophosphamide (CY) is a FDA approved prodrug that has been widely used 
for the last three decades for treatment of Hodgkin's lymphoma, non-Hodgkin's 
lymphoma, cutaneous T-cell lymphoma as many other neoplastic pathological 
conditions [109, 110]. CY is a nitrogen mustard alkylating agent which has the ability to 
add an alkyl group to DNA [111]. This prodrug is converted at the hepatic level to 
active metabolites such as 4-hydroxycyclophosphamide and aldophosphamide [112]. 
CY when administered at low-dosage levels has the ability to suppress Treg cells 
reinstating antitumor immune responses which lead to an increase on survival rates and 
prevention of tumoral reappearance [113-115]. Castano et al. [116] combined high- and 
low-dosage CY with photodynamic therapy in order to evaluate the ability to eradicate 
the tumors. The use of the photodynamic therapy is known to induce cell damage at the 
tumoral level leading to the interruption of nutrient and oxygen supply. These 
conditions ultimately culminate in the occurrence of apoptosis and necrosis triggering 
the formation of tumor antigens that are released into the bloodstream. When 
recognized by the immune system, an immune response will be generated. Castano et 
al. showed that combining CY at a low-dosage level with the photodynamic therapy 
was successful and resulted in a 70 % survival rate over 4 months. The CY or the 
photodynamic therapy when administered in separate contribute to an increase on the 
survival time, however did not impede the animal death. 
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10. Experimental Hypotheses and Experimental Design 
The studies discussed from the literature led to the generation of the following 
hypothesis for this study: 
(1) Human annexin V would be successfully expressed in a soluble and functional 
form in the E. coli bacterial strain; 
(2) The produced annexin V binds selectively to human vascular endothelial cells 
grown in vitro that express PS on their surface; 
(3) The annexin V produced can be conjugated with SWNTs, which will act as 
carriers of the protein and also as heat transducers when irradiated; 
(4) The SWNT-annexin V conjugate (SWNT-Anx V) binds to non-confluent human 
endothelial cells (expressing PS) grown in vitro and these cells with conjugate 
bound can be killed after washing and then laser treatment with no effect on 
cells that were laser-treated with no conjugate present. When injected i.v. in 
mice, the conjugate will accumulate in the tumor, and subsequent NIR 
irradiation will lead to a localized thermal ablation effect and consequent cell 
killing / tumor regression.  
(5) When the immunostimulant cyclophosphamide is injected prior to 
administration of the conjugate and NIR irradiation, there will be more killing of 
the tumor and increased survival, compared to when there was only conjugate 
and NIR irradiation administered. 
In order to verify and confirm our hypotheses, experimentation was done based on 
the experimental design presented below: 
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(1) The expression of the human protein annexin V was performed using a 
prokaryotic expression system – E. coli – due to the fact that is simple to handle, 
cost effective and allows for the production of large amounts of heterologous 
proteins [117]. The presence of a His-tag as the affinity tag allowed for the 
separation of the desired product from any impurities by immobilized metal 
affinity chromatography. The His-tag was removed before the final purification 
step. Storage of the pure protein is done after having the entire sample aliquoted 
and lyophilized. The purity and solubility of the protein was evaluated through a 
SDS-PAGE and Bradford analysis. 
(2) The protein annexin V was biotinylated and incubated with proliferative, non-
confluent human endothelial cells expressing PS on the outer leaflet of the cell 
membrane. After incubation at different concentrations, the unbound protein 
was removed through an extensive washing step. The binding strength was 
determined using a colorimetric assay. 
(3) The attachment of the protein annexin V to the SWNTs was done using an 
intermediate linker. The linker acts as a spacer between the protein and the 
surface of the nanotubes (NTs). This approach allows for the non-covalent 
attachment of the protein to the NTs. The hydrophobicity of the side walls of the 
SWNTs and the linker allows for the establishment of a strong and irreversible 
π-π stacking binding. The NTs are first dispersed in an aqueous surfactant 
solution. The linker molecules are then added and allow for the displacement of 
the majority of the surfactant molecules which are removed through an 
extensive dialysis. The protein is then reacted with the linker through a 
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particular reaction which is different for each linker. Protein and NT 
concentrations are evaluated spectroscopically. The conjugate showing the 
protein surrounding the NT is illustrated by atomic force microscopy (AFM). 
(4) The incubation of the conjugates with cells and their i.v. administration in vivo 
for a certain amount of time allows for the establishment of binding. The 
binding of the SWNT-Anx V conjugate to proliferating endothelial cells in vitro 
was observed using Anx V that was labeled with the fluorescence tag FITC. 
After washing of the cells incubated in vitro or allowing time (24 hours) for 
unbound conjugate injected i.v. to substantially clear from the bloodstream, the 
cells (in vitro) and the tumors (in vivo) are then irradiated using a NIR laser. The 
proposed mechanism for the in vivo binding and subsequent irradiation is 
illustrated in Figure 12. Cell viability or tumor regression is then evaluated using 
the Alamar Blue assay and manual measurements of the tumors every 2 days, 
respectively.  
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Figure 12: Schematic diagram showing the global mechanism of this study. 
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Bacterial Strains and Plasmids 
The plasmid encoding annexin V, pET-30 Ek/LIC/ANX, was previously 
constructed in this lab by Ph. D. student Naveen Palwai [118]. The plasmid is designed 
to express annexin V having an N-terminal (His)6 tag and an HRV 3C protease site next 
to the N-terminus of annexin V. Host strain E. coli BL21 (DE3) (protein expression 
host) and E. coli NovaBlue GigaSingles™ Competent Cells were purchased from 
Novagen (Madison, WI). 
 
Enzymes 
HRV 3C protease and T4 DNA polymerase were acquired from Novagen. 
 
E. coli cell Culture Medium 
NaOH, NaCl, tryptone, kanamycin and yeast extract were purchased from 
Sigma (St. Louis, MO). 
 
Cell Transformation 
SOC medium and kanamycin (Sigma) were used. 
 
Cell Expression 
Isopropyl-beta-D-thiogalactopyranoside (IPTG), TPCK, PMSF and β-
mercaptoethanol were from Sigma. Sodium phosphate was purchased from 
Mallinckrodt Chemicals (Mallinckrodt Baker, Inc., Phillipsburg, NJ). Imidazole was 
obtained from Fisher. 
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Protein Purification  
The HisTrap chromatography column (5 ml) was purchased from GE Health 
Biosciences Corp. (Piscataway, NJ). Flow adapters were purchased from Bio-Rad 
(Hercules, CA). The 3.5 kDa dialysis membrane was from Spectrum Laboratories 
(Rancho Dominguez, CA). 
 
SDS-PAGE 
Laemmli sample buffer, ladder (marker) and Bio-Rad 10x Tris / glycine / SDS 
buffer were purchased from Bio-Rad Laboratories (Hercules, CA) and β-
mercaptoethanol and Coomassie Brilliant Blue R250 were from Sigma.  
 
Cell Culturing and Cell Counting 
Endothelial cells (HAAE-1) were purchased from ATCC (Manassas, VA) (Cat. 
# CRL-2472) and Coriell Institute Medical Research (Camden, NJ) (Cat. # AG09799). 
The cell medium Ham’s F12K (Appendix G) used for the human endothelial cells was 
acquired from ATCC (Manassas, VA). The supplements added to the medium were 
heparin (Polysciences, Warrington, PA), endothelial cell growth supplement (BD 
Biosciences, Bedford, MA), fetal bovine serum (Atlanta Biologicals, Lawrenceville, 
GA), and the antibiotics penicillin and streptomycin (Invitrogen, Grand Island, NY). 
The cells were grown in T-75 flasks (Fisher Scientific, Pittsburgh, PA), 24-well plates 
(VWR International, LLC, Radnor, PA), petri dishes (Falcon, BD Biosciences, Bedford, 
MA), and microscope slide chambers (Fisher Scientific, Pittsburgh, PA). Porcine gelatin 
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was bought from Sigma. The 4T1 cell line and the corresponding RPMI-1640 cell 
medium were acquired from ATCC. 
 
Binding Assay using Human Endothelial Cells 
Biotin and streptavidin-HRP were purchased from KPL (Gaithersburg, MD), 
and OPD  (Appendix E) was from Sigma. The biotin was received in a solid form and 
distributed in equal amounts in several aliquots. The biotin was reconstituted with DMF 
at a concentration of 20 mg/ml and stored at -80 ºC. DMF and H2O2 were obtained from 
Fisher Scientific. Sodium phosphate dibasic was from Mallinckrodt Chemicals 
(Mallinckrodt Baker, Inc., Phillipsburg, NJ). NaCl was purchased from Macron 
Chemicals (Avantor Performance Materials Inc., Phillipsburg, NJ). Bovine serum 
albumin (BSA), CaCl2, EDTA, glutaraldehyde and NH4Cl were obtained from Sigma. 
Slide-A-Lyzer dialysis cassettes (3.5 kDa) were from Thermo Scientific (Rockford, IL). 
The assay was monitored using a BioTek Synergy HT microtiter plate reader 
(Winooski, VT). The dissociation constant determination was done using the GraphPad 
Prism software purchased from GraphPad (La Jolla, CA). 
 
SWNT Suspension Preparation 
Purified and freeze dried (6,5) CoMoCAT SWNTs (batch #000-0031) (average 
diameter 0.8 ± 0.1 nm) were provided by Southwest Nanotechnologies, Inc. (Norman, 
OK). Sodium dodecyl sulfate (SDS, from Mallinckrodt Baker, Inc.), sodium cholate 
(NaC, from Sigma) and low-viscosity sodium carboxymethylcellulose (CMC, from 
Sigma) were used as dispersants.  
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Two-step Coupling of the Protein Annexin V and SWNTs using EDC and NHS 
The linker FMOC-NH-PEG-NHS was purchased from Creative PEGWorks 
(Winston Salem, NC). The intermediate PEG molecule that is present on the linker has 
a molecular weight of 3,400 Da. The 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), hydroxylamine, 2-(N-morpholino)ethanesulfonic acid (MES) and 
N-hydroxy-succinimide, 98% (NHS), 2-mercaptoethanol, and sodium phosphate were 
from Sigma. Spectra-Por® dialysis membranes (2 and 100 kDa) (Spectrum Laboratories, 
Inc., Rancho Dominguez, CA) were used. Bradford protein reagent was from Bio-Rad.  
 
Conjugation of the DSPE-PEG-Maleimide linker to Annexin V Protein 
The DSPE-PEG-Maleimide linker was purchased from Creative PEGWorks 
(Winston Salem, NC). Sodium dodecyl sulfate was from Mallinckrodt Baker, Inc.. A 
Spectra-Por® dialysis membrane (2 kDa) (Spectrum Laboratories, Inc.) was used. L-
cysteine amino acid was acquired from Sigma.  
 
Visualization of the SWNT-annexin V Conjugates using Atomic Force Microscopy 
The mica substrate and AFM metal specimen discs were from Ted Pella, Inc. 
(Redding, CA). The MikroMasch NSC15 cantilevers were purchased from MikroMasch 
USA (San Jose, CA). The MikroMasch cantilevers have a backside aluminum coating, 
force constant of 46 Nm-1 and characteristic resonant frequency of 325 kHz. The 
software used to operate the AFM was Picoview 1.10 (Agilent, Santa Clara, CA), and 
further image processing was achieved using Gwyddion (GNU General Public License). 
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Labeling of the SWNT-annexin V with FITC 
Borate buffer and FITC were purchased from Pierce (Thermo Fisher Scientific). 
Sodium phosphate dibasic was from Mallinckrodt Chemicals. 
 
Cell Staining and Confocal Microscopy 
Microscopic chamber slides were purchased from Thermo Fisher Scientific. 
Microscopic coverslips were from Corning (Corning, NY). Porcine gelatin was acquired 
from Sigma. A Precision Scientific-Low Temperature Incubator 815 was also used 
(Precision Scientific, India). CellMask™ Deep Red plasma membrane stain was from 
Molecular Probes™ (Eugene, OR). Buffered formalin (10 %) was from Richard-Allan 
Scientific (Kalamazoo, MI). Fluoro-gel antifade reagent was purchased from Fisher. 
 
Laser Treatment of Endothelial Cells with SWNT-annexin V on the Cell Surface 
The CaCl2 and Alamar Blue dye were from Sigma. Zap-it
® paper was purchased 
from Zap-it Corporation (Salisbury, NH). The statistical software used was from 
GraphPad InStat from GraphPad. 
 
Assessment of Sterility 
Agar was from Sigma. 
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In Vivo Studies 
The BALB/cJ mice (Appendix L) were purchased from Jackson Laboratory (Bar 
Harbor, ME). Cyclophosphamide was obtained from Sigma. Ketamine and xylazine 
were purchased from Butler Schein (Dublin, OH). Needles (25 and 30 gauge) were 
purchased from Fisher. The syringes and blue mats were from VWR. Matrigel was 
acquired from Fisher Scientific (Fair Lawn, NJ). The digital caliper from Pittsburgh 
(Model 47256, Harbor Freight Tools, Camarillo, CA) and the scale from Ohrus (Model: 
CS 200, Ohaus Corporation, Pine Brook, NJ). 
 
Dissection Studies 
Formaldehyde was purchased from VWR (West Chester, PA). A dissection kit 
was purchased from the Zoology stockroom. 
 
Histology Studies 
The histology studies were performed through the OU HSC and the containers 
used to store the specimens were provided by them. 
 
Biodistribution Study 
The tools used to dissect the animals were purchased from the OU Zoology 
Stockroom. The 10 % buffered formalin was from Richard-Allan Scientific. SDS 
(Mallinckrodt Baker Inc.), Triton-X 100 (Sigma), DTT (Fisher Scientific) and tris-
acetate-EDTA buffer (Sigma) were used to prepare the lysis buffer. Microscope slides 
and 1.5 ml plastic cuvettes were acquired from the OU Chemistry Stockroom.  
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Expression, Cell Lysis and Purification of the Recombinant Protein Annexin V 
BL21 (DE3) cells harboring the pET- 30 Ek/LIC plasmid with the annexin V 
gene (50 µl) were cultured in 10 ml of fresh LB medium (Appendix A.1.1.) containing 
35 µg/ml kanamycin overnight with constant shaking (250 rpm) at 37 ºC in an incubator 
shaker (VWR 1585 Shaking Incubator, Sheldon Manufacturing, Inc., Cornelius, OR). 
The overnight cell culture (10 ml) was inoculated into 1 L LB medium, containing the 
same kanamycin concentration. Cell growth was monitored by measuring the 
absorbance of the sample at 600 nm (Shimadzu UV-2100PC UV-VIS Scanning 
Spectrophotometer, Japan). IPTG was added to a concentration of 0.6 mM to induce the 
expression of recombinant annexin V when the optical density (600 nm) of the culture 
reached 0.4-0.6. The cells were stirred for an additional 5 h at 30º C in a VWR 1585 
Shaking Incubator shaker at 250 rpm and centrifuged at 10,000 x g for 10 min in a 
Beckman J2-21 refrigerated centrifuge (Beckman Instruments, Inc., Palo Alto, CA). 
The soluble part was resuspended in 20 ml of sonication buffer (0.05 mM N- p-tosyl-L-
phenylalanine chloromethyl ketone (TPCK), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 0.01 % β-mercaptoethanol and 0.02 M sodium phosphate at pH 7.4). A vortex 
(Model: G-560, Scientific Industries Inc., Bohemia, NY) was used to help resuspending 
the cells. The cells were then sonicated (Sonic Dismembrator, Fisher Scientific, 
Springfield, NJ) causing cell lysis. The process was performed at 4 ºC using 4.5 
watts/ml of lysate for a total time of 150 sec. In order to remove cell debris, the cell 
lysate was centrifuged at 12,000 x g for 30 min.  
At this point, the purification was started with all of the steps being performed at 
4 ºC. The loading of the different solutions into the 5 ml HisTrap chromatography 
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column (GE Healthsciences, UK) was performed by a Gilson Minipulse 3 peristaltic 
pump (Gilson Medical Electronics, Inc., Middletown, WI). The entire chromatography 
system was cleaned and calibrated using 25 ml of wash buffer (20 mM sodium 
phosphate, 40 mM imidazole, 500 mM NaCl at pH 7.4). The cell lysate was mixed with 
40 mM imidazole (Fisher Scientific) and 500 mM of NaCl and then loaded onto the 
chromatography column. Next, the wash buffer was flowed through the column in order 
to wash it. Elution buffer was added next (20 mM sodium phosphate, 500 mM 
imidazole, 500 mM NaCl at pH 7.4) to promote the elution of the His-tagged annexin 
V. Fractions containing the purified protein were detected by an Isco UA-5® UV-Vis 
spectrophotometer (Isco, Inc., Lincoln, Nebraska) at 280 nm.  
In order to extract imidazole and NaCl from the protein solution and establish 
favorable conditions for N-terminal His-tag cleavage, dialysis was performed [119]. 
Eluted protein was collected into a 12 kDa dialysis membrane that was immersed in a 
dialysis buffer (20 mM sodium phosphate at pH 7.4). The dialysis process was 
performed overnight at 4 ºC using a magnetic stirrer to improve dialysis efficiency. 
After dialysis, HRV 3C protease was used for the cleavage step, which assures the 
removal of the N-terminal His-tag. HRV 3C protease (0.5 Units / mg of protein) and 
HRV 3C protease cleavage buffer (1.5 M NaCl, 0.5 M Tris-HCl, pH 7.5) were added to 
the protein solution. This reaction was performed at 4 ºC for 8 h. 
Imidazole (40 mM) and NaCl (500 mM) were mixed with the cleaved protein 
solution and this solution was loaded onto the 5 ml HisTrap chromatography column. 
Pure annexin V was eluted using a linear gradient (Bio-rad, Hercules, CA) of 0-0.5 M 
imidazole. The pure protein was dialyzed against a dialysis buffer (20 mM sodium 
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phosphate buffer at pH 7.4 and containing 0.1 M NaCl). The final solution was split into 
several vials (1 mg of protein / vial), which were then instantaneously frozen by 
immersing them in a liquid nitrogen tank. These vials were then freeze dried (see 
Appendix A.2.4) and stored at -20 ºC. 
The final yield of the run was determined by evaluating the protein 
concentration of the final solution using the Bradford protein assay (see Appendix 
A.2.2). A summary of the steps involved in the purification is illustrated in Figure 13. 
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Figure 13: Protein purification flow diagram. 
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SDS-PAGE and Amino Acid Sequencing  
The purity and molecular weight of the recombinant protein annexin V were 
determined using SDS-PAGE. A Bio-Rad Mini-Protean 3 cell gel electrophoresis unit 
(Bio-Rad, Hercules, CA) and an Integrated Separation Systems (ISS-emprotech ISS 
500) power supply were used for the SDS-PAGE analysis. The SDS-PAGE gel was 
prepared with 12 % (w/v) acrylamide, 1.5 M Tris-HCl, pH 8.8, 10 % (w/v) SDS. 
Electrophoresis buffer was prepared using 10 % 10x Tris/glycine/SDS buffer and 90 % 
deionized water (dH2O). Each sample (10 µl) was loaded into each individual well of 
the gel. The gel was run at a constant voltage for about 1 h. The separating gel was 
stained with 45 % (w/v) dH2O, 45 % (w/v) methanol, 10 % (v/v) acetic acid, and 0.25 
% (w/v) Coomassie Brilliant Blue R250 for 1 h with constant shaking. The SDS-PAGE 
analysis was done using the UN-SCAN-IT gel™ - Gel Analysis software (Silk 
Scientific, Orem, UT). The detailed protocol is given in Appendix A.2.3. The amino 
acid sequencing for the first 6 amino acids of the protein sample was done through 
OMRF. 
 
Cell Culturing and Cell Counting 
Endothelial cells (HAAE-1) (Appendix F) were used for all of the in vitro assays 
in this study. The cell medium used was Ham’s F12K cell medium with 2 mM L-
glutamine adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 0.1 
mg/ml heparin and 0.03 mg/ml endothelial cell growth supplement, 90 %; fetal bovine 
serum, 10 %. The antibiotics penicillin and streptomycin were also included in the 
medium at 100 U/ml and 100 µg/ml, respectively. The cells were grown in T-75 flasks, 
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24-well plates, petri dishes, and microscope slide chambers. The procedures followed 
for the cell growth were provided by the American Type Culture Collection. A detailed 
protocol for the cell growth and passaging is included in the Appendix O. The cell 
number was determined by cell counting using a hemacytometer (Appendix J). The 
desired number of cells to add to each T-75 flask after cell passage must be 
approximately equal to 5 x 104 cells.  
The in vivo studies which were performed at a later stage required the usage of a 
different cell line in order to mimic and reproduce conditions which are similar to the 
human breast cancer. The 4T1 cell line is an appropriate line to induce tumors in the 
BALB/c mice and when injected they produce tumors that are highly metastatic [120, 
121]. The main metastatic sites for this cell line are the lung, liver, brain and lymph 
nodes. This tumor resembles a stage IV for the human breast cancer. When growing the 
cells, it is important not to let the cells reach confluence, and they should be subcultured 
when they reach approximately 80 % of confluence. The subcultivation ratio 
recommended is 1:6 or 1:8. In order to grow this cell line in vitro, it is necessary to 
supply the cells with the appropriate full medium which is composed by RPMI-1640 
medium (Appendix N) enriched with 10 % FBS and penicillin/streptomycin antibiotics 
(100 U/ml and 100 µg/ml, respectively). These cells do not require gelatin as a substrate 
and can be grown directly in the T-75 flasks. When plating the cells, a frozen vial is 
allowed to thaw in a water bath for 1 min. and then mixed with 9 ml of warm cell 
medium. Centrifugation at 1,100 rpm for 5 min. using a Mistral / MSE 3000 E 
Centrifuge (Leicestershire, England) was performed. The majority of the supernatant is 
then discarded leaving only 1 ml in the centrifuge tube. Warm medium (9 ml) is then 
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added to the tube and mixed evenly using a plastic pippetor. The cells are then 
transferred to the T-75 flask. The subcultivation from one T-75 to eight T-75 flasks was 
performed on the following day. On the third day, the cell medium was replaced with 
new one, which had a slightly different formulation. This new cell medium was 
supplemented with 10 % FBS, but the antibiotics were not added. The cells were grown 
in a Precision Scientific-Low Temperature Incubator (Model: 815, The Precision 
Scientific Co., India). A hemacytometer from Hausser Scientific (Horsham, PA) was 
used for cell counting. 
 
Binding Assay using Human Endothelial Cells 
The biotin-streptavidin interaction was used to determine the dissociation 
constant for the binding of the protein annexin V to the endothelial cells. The use of 
streptavidin-HRP allowed for the quantification of the binding by using a reducing 
agent – O-phenylenediamine (OPD) that changes color when in the presence of HRP 
(horseradish peroxidase). That color change can easily be monitored by measuring the 
absorbance at 492 nm on a plate reader. The dissociation constant was determined for 
the specific, non-specific and total binding. A detailed protocol is included in the 
Appendix Q.  
 
SWNT Suspension Preparation 
The SWNTs by themselves tend to aggregate and form bundles. In order to 
prepare these structures for this study, it was required to suspend them in an aqueous 
medium. For that, 6 mg of SWNTs were mixed with 7 ml of a 1 % SDS solution. The 
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suspension was then sonicated for 30 minutes at 19.8 W of power (E = 35,640 J) (Horn 
Sonic Dismembrator, Model 500 from Fisher Scientific). A 30 min centrifugation was 
performed at 15,000 rpm (26,000 x g) in order to discard any aggregates. Sonication 
and centrifugation were performed twice in order to enhance the purity of the final 
samples. The conjugate was then stored in a small glass bottle at room temperature. A 
characteristic dark-colored aqueous suspension was obtained as result of this sonication 
process (Figure 14). 
 
 
 
 
 
Figure 14: SWNTs suspended in sodium cholate. 
 
Part of the suspension (1 ml) was saved for further NIR spectral analysis (note 
that this was an optional step and it was not always performed). In order to obtain 
suspensions with shorter nanotubes, the sonication times were increased to 3 h leading 
to a total of 6 h sonication. The carbon nanotubes size was then measured using atomic 
force microscope (AFM) (Digital Instruments, Model Dimension 3100 Atomic Force 
Microscope, Veeco Metrology Group, Plainview, NY). 
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Two-Step Coupling of the Protein Annexin V and SWNTs using EDC and NHS 
The coupling of the protein annexin V using EDC and NHS (Appendices C and 
D) was done by mixing 779 µl of the FMOC-NH-PEG-NHS linker (using a 1 mg/ml 
solution) with 7 ml of the nanotube suspension (prepared previously) for 30 min at 
room temperature and using gentle shaking. An 8 h dialysis followed using a 2 kDa 
dialysis membrane.  The dialysate (2 L of deionized water) was changed after the first 4 
h. The main purpose of this initial dialysis was to remove any excess of SDS molecules 
that were present in the suspension and to replace some of the SDS molecules with the 
linker molecules. The linker molecules, which have a molecular weight of 3,777 Da, 
will be retained by the dialysis membrane while the SDS molecules (M.W. = 288.38 
Da) will be able to cross the membrane freely. The removal of the excess of SDS will 
also prevent interactions with the protein annexin V which could eventually cause 
protein denaturation. At this step, the nanotubes will continue dispersed and in 
suspension, and each of them will have linker molecules adsorbed on their surface. It is 
also known that during the dialysis, the succinimide group present on the linker 
becomes hydrolyzed and it gets converted into a carboxyl group.  
The coupling reaction was started by adding one part of an activation buffer to 
nine parts of the suspension. The activation buffer was prepared using 5 M NaCl and 1 
M MES (pH = 6.0) in an aqueous medium. A 1 h centrifugation at 29,600 x g 
(Eppendorf 5424 Centrifuge) was performed in order to remove some possible SWNTs 
aggregates. EDC and NHS were allowed to equilibrate at room temperature prior to 
adding them to the suspension. EDC (2 mg, 2 mM) and 3 mg of NHS were added to 5 
ml of the SWNT suspension and mixed for 15 min at room temperature. The EDC was 
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then quenched by adding 7 µl of 2-mercaptoethanol (20 mM). Next, the protein vial was 
reconstituted by adding deionized water to the lyophilized vial. Protein solution (571 µl, 
0.824 mg) was added to 874 µl of the suspension and allowed to mix with gently 
shaking for 2 h at room temperature. Hydroxylamine was added to a final concentration 
of 10 mM in order to quench the reaction. This step allows the hydrolysis of the non-
reacted NHS present on SWNT-annexin V and results in the regeneration of the original 
carboxyl groups. A final dialysis step was performed at 4 ºC in order to remove any 
unbound protein annexin V. The 8 h dialysis was performed using a 100 kDa dialysis 
membrane. 20 mM sodium phosphate (1 L, pH 7.4) was used as buffer which was 
replaced after 4 h. The 8 h dialysis requires the use of a 100 kDa dialysis membrane 
which has pores that are large enough to allow the protein annexin V to migrate. All of 
the dialysis steps were performed with constant stirrer agitation. A 1 h final 
centrifugation was performed at 29,600 x g in order to remove any SWNTs aggregates. 
An Orbit water bath shaker (Lab-line Instruments, Inc., Melrose Park, IL) was used to 
mix the solutions. 
The concentration of the protein was determined by Bradford protein assay. The 
SWNTs concentration was measured by reading the absorbance at 800 nm using a 
spectrophotometer. Protein and nanotube concentration were measured using a 
Shimadzu UV-2101 PC UV-Vis spectrophotometer (Shimadzu, Japan). 
 
Conjugation of DSPE-PEG-Maleimide linker to Annexin V protein 
In order to perform the conjugation of the DSPE-PEG-Maleimide linker to the 
protein annexin V, a suspension of SNWTs was prepared using the protocol described 
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for the FMOC-NH-PEG-NHS linker using 6 mg of SWNTs per 5 ml of 1 % SDS. The 
linker (M.W. = 4,368 Da) was then dissolved at a concentration of 1.5 mg/ml using a 
solution of 1 % SDS. The linker was then stored at -20 ºC under a nitrogen atmosphere. 
Linker solution (1 ml) was mixed with 5 ml of the SWNT suspension. The solution was 
then mixed at room temperature for 30 min with gentle shaking. After that, the 
suspension was transferred into a 2 kDa dialysis membrane and allowed to be dialyzed 
for 8 h against 2 L of deionized water. The dialysate was changed after 4 h. Annexin V 
(5 mg) was then reconstituted with 1 ml of deionized water. The SWNT-linker (2 ml) 
suspension was mixed with the reconstituted annexin V at room temperature for 2 h 
with gentle shaking. Any unreacted linker sites were blocked with L-cysteine (0.048 
mg) which was added to the suspension and allowed to react for 1 h at room 
temperature with gentle shaking. The molar ratio of L-Cys/Linker was equal to 3:1. The 
suspension was then dialyzed for 8 h against 2 L of 20 mM sodium phosphate buffer at 
pH of 7.4. The dialysate was changed after 4 h. The dialysis was performed using a 100 
kDa dialysis membrane, in order to allow for the removal of any unbound annexin V or 
L-cysteine present in excess. The final suspension was then centrifuged at 13,000 rpm 
(15,680 x g) for 1 hour in order to remove any aggregates. The nanotube and protein 
concentrations were then evaluated using the same procedures as for the FMOC-NH-
PEG-NHS linker. The conjugate was stored at 4 ºC until use. An Eppendorf 5424 
Centrifuge (Eppendorf, Hamburg, Germany) was used.  
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SWNTs Conjugates Characterization 
A Raman analysis was performed using the final conjugate. The sample was 
analyzed in a Jovin Yvon-Horiba Lab spectrophotometer, equipped with a CCD 
detector and with a He-Ne laser (excitation of 633 nm). The SWNT-annexin V aqueous 
suspension was spread on a Si/SiO2 surface prior to analysis. An optical absorption 
spectra was also acquired by using a Lambda 950 UV-Vis-NIR spectrophotometer 
(Perkin Elmer, Waltham, MA). 
The Si / SiO2 substrate was prepared by Verónica (former graduate student 
working in Dr. Resasco’s laboratory). The absorption spectra were acquired at 
SouthWest NanoTechnologies by Dr. Tan. 
 
Visualization of the SWNT-annexin V conjugates using Atomic Force Microscopy 
 The visualization of the SWNT-annexin V conjugates was done using AFM. 
The Agilent 5420 AFM was set up to use the tapping mode. All images were acquired 
at 512 samples per line at 1 µm and for clearer images 1,024 samples per line at 1 µm 
were used. The SWNTs suspension was diluted 50 X with deionized water and 
deposited through slow spin coating (500 rpm) on a freshly cleaved mica surface. 
Samples were then dried in a vacuum oven at room temperature for 5 h, allowing for 
water evaporation. 
 
Labeling of the SWNT-annexin V with FITC 
The visualization of the endothelial cells after being incubated with the 
conjugate is our goal, allowing us to verify the binding of this conjugate in vitro. In 
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order to establish a procedure for the visualization of the endothelial cells and the 
conjugates, it was necessary to label the conjugate with a fluorophore molecule, such as 
one that emits photons with a characteristic wavelength of green. The green color is 
conferred by the fluorescein isothiocyanate (FITC) molecules which were previously 
bound to the conjugate (SWNT-annexin V). The labeling of the conjugate allows for the 
generation of conjugates that will emit green light when exposed to a laser of a certain 
wavelength (490 nm). The conjugation of FITC with the SWNT conjugates was done 
by having the SWNT-annexin V conjugate prepared as described earlier. The conjugate 
suspension (460 µl) was mixed with 40 µl of borate buffer. FITC solution (50 µl, 1 
mg/ml) was then added to the suspension. This was incubated with gentle mixing at 
room temperature for 1 h. All of the steps involving the dye were done in a controlled 
environment protected from the light. The excess of FITC was removed by dialysis 
(using a 3.5 kDa Slide-A-Lyzer dialysis cassette) against 2 L of 20 mM sodium 
phosphate buffer (pH 7.4) for 7 h, with a change of buffer after 4 h. The conjugate was 
then stored at 4 ºC protected from light.  
 
Cell Staining and Confocal Microscopy 
Endothelial cells were grown to approximately 75-80 % confluence in T-75 
flasks as described previously. The cells were then seeded in chamber microscope slides 
and allowed to growth for 24 h. Partial confluence was achieved after that incubation 
period, and it is important to verify the confluency level prior to the start of this 
experiment. Partial confluence allows for the mimicking of active and proliferative cells 
that are present at the tumoral level in vivo. The cells were then incubated for 2 h at 37 
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ºC with SWNT-FITC-annexin V at a concentration of 6 mg/L. This was followed by an 
extensive wash step and by staining with CellMask™ Deep Red plasma membrane stain. 
The entire protocol is described on Appendix P. The acquisition of the confocal 
microscopy images was done using the procedures established by the confocal 
microscopy laboratory. The confocal pictures were taken using an Olympus FluoView 
500 Microscope at the Electron Microscope facility at OU (Olympus America 
Corporate, Center Valley, PA). The confocal laser scanning microscope is equipped 
with different lasers, which we used for green (excitation with blue Argon laser at 488 
nm) and red (excitation with green Helium Neon laser at 543 nm) emissions. The 
images were processed using the Fluoview software (Olympus America Corporate, 
Center Valley, PA). 
 
Laser Treatment of Endothelial Cells with SWNT-annexin V on the Cell Surface 
The laser treatments were conducted using two sets of endothelial cells –
confluent and non-confluent. The cells that were previously grown in T-75 flasks were 
seeded into 24-well microtiter plates. The suspension of the SWNT-annexin V was 
incubated for 2 h at a concentration of 6 mg/L and at 37 ºC. A washing step (300 µl) 
followed the incubation using cell medium containing 2 mM CaCl2. Each set had four 
sample groups which were each evaluated in triplicate. Different controls were studied 
in order to guarantee the specificity of the assay. Two controls were intended to study 
the effect of the laser irradiation by itself on the cell viability, and the cytotoxicity of the 
SWNTs conjugates alone. A final control was composed of cells that were not irradiated 
or incubated with the conjugate. Each plate subjected to the laser treatment was 
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irradiated for 120 sec at 2.92 W (energy density = 350 J/cm2) using a Diodevet-50 NIR 
laser at 980 nm (B&W Tek Inc., Newark, DE). The distribution of the samples on the 
plate is illustrated on Figure 15. 
 
 
 
 
 
 
 
 
 
Figure 15: The disposition of the samples within the 24-well plate. The shadowed wells 
represent the wells that received cells and were subjected to the laser irradiation. The 
red circle represents the size of the NIR laser beam when irradiating the sample. The 
irradiation was always performed by having the plate sitting on top of a platform and 
with the optical fiber placed few centimeters away from the bottom of the plate in order 
to obtain the desired size beam. The size of the beam was adjusted using a laser 
sensitive paper (Zap-it® paper) which burns when exposed to a laser beam. The entire 
irradiation session was conducted by having the cells under a sterile environment by not 
removing the lid of the plate. 
 
r = 2.2 
cm 
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The attenuation of power from the fiber was determined by a power meter 
(Ophir Optronics Ltd., Israel). The laser beam was delivered by an optical fiber placed a 
few centimeters from the bottom of the plate below the well. Each well was carefully 
adjusted in order to be centered with the laser beam. The size of the beam was adjusted 
using a laser sensitive paper (Zap-it® paper) which burns when exposed to a laser beam 
and allows the visualization of the intensity of the beam. Cutting a small circle of this 
paper and placing it on the bottom of the well permits to determine if the entire well is 
being subjected to the irradiation. After having the fiber completely aligned with the 
well, the power attenuation inherent to the optical fiber and to the plate was determined 
by using the power meter. The power meter probe was placed on top of a microtiter 
plate (without the lid on) and the power was determined. The entire irradiation was 
done at room temperature keeping the cover of the plates on, maintaining the sterility of 
the samples. The cell viability was determined by using the Alamar Blue assay. The 
Alamar Blue evaluates the metabolic activity of the cells, and it is basically a non-
fluorescence indicator dye (resazurin) which gets reduced in the presence of 
metabolically active cells [122]. When reduced, the resazurin gets converted into a 
bright-pink fluorescent resofurin as illustrated on Figure 16. The Alamar Blue is 
performed by adding 10 % to the cells followed by a 4 h incubation at 37 ºC. The 
colorimetric changes are then evaluated by measuring absorbance or fluorescence. The 
complete protocol is given in Appendix K.  
 
 
 
53 
 
 
 
 
Figure 16: Chemical mechanism illustrating the reduction of the resazurin dye when in 
the presence of metabolic active cells [122]. 
 
The data was further analyzed using a one-way ANOVA in conjunction with the 
Tukey method. The statistical analysis was performed using the GraphPad InStat 
software with different confidence intervals. 
 
Optical pictures 
The optical pictures were taken using a Nikon D50 (Nikon, Thailand) camera 
which was directly attached to an Olympus CKX41SF microscope (Olympus, Co., 
Japan). 
 
Assessment of sterility 
The sterility of the SWNT-annexin V conjugate needs to be guaranteed prior to 
the in vivo injection in the mice. This will minimize any immune response or infection 
in the animal. In order to sterilize the conjugates, the entire suspension was placed in a 
small petri dish, which allowed the entire suspension to form a thin layer uniformly 
distributed. The suspension was then subjected to a direct UV (UV-C, shortwave UV at 
254 nm) irradiation for 30 min in a sterile environment. The samples were sterilized in a 
regular laminar flow hood equipped with a Philips UV-C lamp (30 Watts). The 
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temperature during the sterilization was monitored, and there were no significant 
increases during the entire process. The samples were then stored in an aseptic vial. 
Further sterility evaluation demonstrated the absence of microorganisms in the samples. 
That assay was done by plating tap water, non-sterile, and sterile SWNTs suspensions 
in a agar plate enriched with LB medium.  
 
In vivo Studies 
The BALB/cJ mice received from Jackson Laboratory (Bar Harbor, ME) were 6 
weeks of age and female. Animal experimentation was not started until the animals 
were 9 weeks old. The animals were kept in a dedicated room in the animal facility 
located in the Zoology building of the University of Oklahoma. All of the protocols 
used involving animals were previously submitted and approved by the Institutional 
Animal Care and Use Committee (IACUC). All of the animals were placed in 
appropriate cages with food and water in an adequate environment. Each cage hosted 
five animals. The anesthetics used were ketamine (100 mg/ml) and xylazine (20 
mg/ml). In order to prepare the anesthetic solution, 1 ml of ketamine (100 mg/ml) was 
mixed with 0.5 ml of xylazine (20 mg/ml) and 8.5 ml of sterile saline solution (0.9 % 
NaCl). The dosage used for each animal was equal to 0.1 ml of the stock solution per 10 
grams of body weight. Prior to anesthesing the animals, each of them was weighted 
using a scale. The protocol followed for the anesthesia is shown in the Appendix R. For 
the tail vein injections, the protocol presented in the Appendix S was followed. 
In order to evaluate the ability to eradicate the tumors using this therapy in vivo, it was 
necessary to implant a suitable cancer cell line in the animals. The 4T1 cell line was 
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chosen for this study, since these cells have the ability to replicate at a fast rate and also 
develop visible tumors in BALB/c mice in a matter of less than one week after 
implantation. The methods used to grow these cells in vitro were previously described 
on the Cell Culturing and Cell Counting section of this chapter. After having the eight 
T-75 flasks growing for 2 days, there are plenty of cells to inject the animals, for each 
test. The cells are then lifted from the flasks using Accutase (Appendix I, trypsin can 
also be used–Appendix H), using the same procedure as for human endothelial cells. 
The cells are then resuspended in 80 ml of cell medium prior to cell counting. Knowing 
that it is necessary to inject 5 x 105 cells / animal (volume = 100 µl), the total number of 
cells was determined. The cell concentration in the sample was evaluated using the 
standard cell counting procedure. The required cells per animal were then placed in 
Eppendorf vials and immersed in a chilled water bath. Matrigel was also placed in 
Eppendorf vials (volume = 100 µl), and transferred to the water bath. This water bath 
had the function of keeping the cells and the matrigel cold during the transportation of 
the materials to the animal facility. 
 As a basis of our theory, the laser irradiation would be responsible for heating 
within the tumor. In order to check this hypothesis in vivo, the animals were injected i.v. 
with suitable nanotube suspensions conjugated with the protein annexin V. Before 
performing those tests, the irradiation safety level had to be determined for the mice. It 
was important to evaluate the highest energy level tolerated by the animals without 
compromising their normal functions. For these tests three different energy levels were 
used: 200 J/cm2, 300 J/cm2 and 400 J/cm2. Prior to the laser irradiation, the three mice 
used were shaved on the flank using a multipurpose electric razor. The fur must then be 
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removed in order to eliminate any attenuation of laser energy due to blocking. This will 
help maximize the amount of energy delivered on the region of interest. The area of the 
irradiating beam was equal to 1.77 cm2 for the majority of the animals. When necessary 
the beam size was adjusted to a larger size in order to make sure that the entire tumoral 
region was being irradiated. The three animals were anesthetized prior to the irradiation 
session. The power used was 1 W/cm2.  
Intratumoral injections of the SWNT-annexin V conjugated were also performed 
in order to evaluate the efficiency of the treatment when comparing with the i.v. 
injections. For this study four mice were used.  
 For the main photodynamic therapy study, 36 animals were used. The animals 
were separated into six different groups: Untreated, SWNTs, Laser, SWNTs+Laser, CY 
and CY+SWNTs+Laser (CY: cyclophosphamide). The first three groups and the CY 
group were control groups that were used as comparison with the treatment groups 
(SWNTs+Laser and CY+SWNTs+Laser). When the average tumors volume was 
approximately equal to 60 mm3, the therapy was started. At that point, the CY and 
CY+SWNTs+Laser groups received the pro-drug cyclophosphamide i.p. at a dosage of 
50 mg/kg. Twenty four hours post-administration the animals from the SWNTs, 
SWNTs+Laser and CY+SWNTs+Laser received an i.v. administration of the SWNT-
annexin V conjugates. The laser irradiation of the animals from the Laser, 
SWNTs+Laser and CY+SWNTs+Laser groups was conducted 24 h later. 
After irradiation, the tumor volumes were monitored every two days. This was done in 
order to verify the efficiency of the treatment and compare the sizes among the different 
groups. Prior to the measurements, the animals were sedated and then they were also 
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weighted using a scale. The length and width of the tumors was measured using a 
digital caliper. The tumor volumes were determined by applying the following formula: 
 [94]. 
Dissection Studies 
In order to perform the histology analysis, it was necessary to euthanize the mice 
and extract the tumors and also the lungs. Since this particular type of cancer line is 
known to metastasize to the lungs, it was important to check for the presence of nodules 
on those organs. The animals after being used in the previous in vivo studies were 
euthanized following the protocol recommended by the OU IACUC. The animals were 
then dissected using appropriate dissecting tools acquired from the OU Zoology 
stockroom. The animals were open through the abdominal side and an example of the 
method used is illustrated on Figure 17. 
 
Figure 17: General view of a dissected mouse prior to organ extraction [123]. 
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After exposing the internal organs, the lungs and the tumors (actively grown in 
the flank region) were carefully extracted and placed in appropriate containers 
previously filled with 10 % formalin (or 4% formaldehyde solution diluted with PBS). 
The carcasses of the animals were appropriately disposed of following the OU IACUC 
guidelines. The containers were appropriately sealed and stored overnight in the 
refrigerator. The samples can be stored for several weeks under these conditions 
without major problems. 
 
Biodistribution study 
In order to study the biodistribution profile of the SWNT-annexin V conjugate 
when injected i.v. in vivo, two animals were used. The animals were subjected to the 
same conditions as the other group of animals that were part of the main photothermal 
study. The animals received a subcutaneous injection of 4T1 breast cancer cells in the 
flank region. When the average tumors’ volume was approximately equal to 60 mm3, 
the animals received an i.v. administration of the nanoconjugates (150 µl at a 
concentration of 109.1 mg/L, average dosage = 0.82 mg/kg). The animals were 
sacrificed 24 h later, and the organs and tissues of interest were collected. Lungs, livers, 
and tumors were preserved and stored in 10 % formalin at 4 ºC for further evaluation. 
Raman spectroscopy was the technique used to quantify the concentration of the single- 
walled carbon nanotubes present in the organs. The Raman system used was the Nicolet 
NXR 9610 FT-Raman from Thermo Electron Corporation (λYAG Laser = 1,064 nm). The 
system is property of the Chemistry Department at the Oklahoma State University under 
the supervision of Dr. Barry Lavine, who kindly evaluated the samples for us. The 
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Fourier transform Raman (FT-Raman) has the ability to decrease sample’s fluorescence 
that could mask the Raman signals from the SWNTs. The FT-Raman system has an 
interferometer installed, which generates an interferogram. This set of data contains all 
of the Raman signal frequencies encoded. The signal is acquired in a very fast and 
accurate way allowing for the acquisition of 64 scans in less than 2 minutes. The 
interferogram is then converted into the final Raman spectrum by a computer that is 
attached to the system.  
The characteristic G band seen at 1590 cm-1 was our reference. Based on the fact 
that Raman spectroscopy allows for a qualitative and quantitative evaluation, a 
calibration curve was obtained using known concentrations for a reference sample 
(SWNT suspension) in lysis buffer (1% SDS, 1% Triton-X 100, 10 mM DTT, 40 mM 
tris-acetate-EDTA buffer). While obtaining this curve, it was possible to determine the 
limit of detection for this particular equipment, which means that below a certain 
nanotube concentration it is not possible to detect a significant light scattering intensity 
for the G band region. The Raman system has the ability to evaluate the scattering 
intensity from the samples using two different modes. The sample can either be placed 
in a Ge metallic disk (drop deposition method, which is further dried at room 
temperature) or in a 1.5 ml plastic cuvette (liquid sample). In order to be able to 
measure the Raman signal from the specimens, the samples were sliced and mixed with 
a lysis buffer solution (1% SDS, 1% Triton-X 100, 10 mM DTT, 40 mM tris-acetate-
EDTA buffer). Each individual sample was then sonicated for 1 minute at 25 % of the 
total power. The samples were then subjected to heating at 70 ºC for 2 h in a water bath. 
This resulted in obtaining clear samples as described by Liu et al. [124]. Samples were 
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also subjected to a 1 h centrifugation step at 15,000 rpm (Eppendorf 5424 Centrifuge) 
which allowed for the physical separation of the cell debris and the SWNTs suspended 
in the lysis buffer. Raman evaluation was performed for all of the samples after the 
centrifugation step. Some of the samples were also further diluted using distilled water.  
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Overexpression and Purification of Annexin V 
 Induction of E. coli containing the pET-30 Ek/LIC/ANX plasmid using IPTG at 
0.6 mM for 5 h at 30 ºC resulted in annexin V being overexpressed in soluble form. 
Pure annexin V was obtained in the second immobilized metal affinity chromatography 
(IMAC) near the beginning of the linear 0-0.5 M imidazole gradient. Since any annexin 
V with the His6 tag still attached would remain on the column, the annexin V eluted in 
the second IMAC (after the His6 tag was cleaved of by HRV 3C protease) does not have 
the His6 tag.  
The annexin V obtained at the end of the purification was analyzed by SDS-
PAGE gel electrophoresis followed by Coomassie Blue staining in order to quantify the 
protein purity. For comparison, bovine serum protein was also analyzed. Figure 18 
shows the purity of the annexin V obtained after the expression, purification, and freeze 
drying processes. The markers indicate that the purified annexin V is close to its 
theoretical molecular size (36 kDa). The purity of annexin V was estimated to be 
greater than 99 % using UN-SCAN-IT gel densitometry software (Silk Scientific, Orem, 
UT). The average yield from 1 L of culture for the different runs was 49.9 ± 10.3 mg 
(n=4). 
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Figure 18: SDS-PAGE analysis using a 12 % gel of purified annexin V. Coomassie 
Brilliant blue was used for staining. The sample size was 10 µl. Lane M, marker ladder 
(Bio-Rad, Hercules, CA) with the indicated molecular masses. Lane 1, annexin V 
prepared at 1 mg/ml after the freeze drying step; Lane 2, bovine serum albumin 
prepared at 1 mg/ml. 
 
Binding Assay using Human Endothelial Cells 
The specific binding of biotinylated annexin V to human endothelial cells in 
vitro was evaluated using a colorimetric assay. HRP reacts with H2O2 (substrate), and 
then reacts with a chromogenic substrate (OPD) which gives a soluble colored product. 
The non-specific binding, obtained in the absence of Ca2+, is subtracted from the total 
binding to obtain the specific binding, as shown in Figure 19. The dissociation constant 
value for the specific binding was determined to be equal to 0.8 nM. The dissociation 
constant is defined as an equilibrium constant for a reversible binding. The Kd 
represents the concentration of the annexin V (ligand) that is needed to have half of the 
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binding sites occupied (PS). The Kd is inversely proportional to the degree of binding 
strength. The value obtained for the dissociation constant is characteristic of a strong 
binding capacity, and it is within the expected range [125]. The plot (Figure 19) 
suggests the existence of a plateau for high concentrations of annexin V, which can be 
interpreted as where the PS binding sites are saturated. This information is of our 
interest for the development of the tests of laser treatment of endothelial cells with 
SWNT-annexin V bound on the cell surface, allowing for the use of a concentration that 
is high enough to saturate all of the binding sites. The data generated by the software is 
shown in Table 1. The dissociation constant value was on the lower side of the range 
found in the literature [26], which is characteristic of a strong binding. 
 
 
Figure 19. Total, specific, and non-specific binding of biotinylated annexin V to human 
endothelial cells (80-85% confluence level) in vitro on a 24-well plate with 1 mM H2O2 
added to expose PS on the cell surface. For the non-specific binding data, no calcium 
was present in the medium. The dissociation constant value for the specific binding was 
determined to be 0.8 nM. 
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Table 1: Data generated by Graphpad software in the determination of Kd for the 
binding of annexin V to endothelial cells. 
Nonlin fit 
A B C 
Total Binding 
Non-Specific 
Binding 
Specific 
Binding 
One site -- Specific binding       
Best-fit values       
    Kd 0.800 64.4 0.846 
Std. Error       
    Kd 0.316 1120 0.189 
95% Confidence Intervals       
    Kd 
-0.013 to 
1.612 -4760 to 4890 0.032 to 1.660 
Goodness of Fit       
Degrees of Freedom 5 2 2 
    R
2
 0.928 0.418 0.941 
Number of points       
    Analyzed 7 4 4 
 
Characterization of SWNT Suspensions 
The centrifugation of the solution containing the nanotubes in suspension with 
sodium dodecyl sulfate gave a solution with nanotubes largely dispersed (individually), 
because of the high g force used for centrifuging. The SWNTs suspensions obtained had 
a homogeneous and non-translucent appearance. There was no visible difference 
between the suspensions that were sonicated for 1 h and 6 h. They were stable for 
several days without major aggregation when stored at room temperature. Figure 20 
shows NIR absorbance spectra for a sample of suspended nanotubes that were 
conjugated with the protein annexin V compared to SWNTs suspended only using SDS 
(control). The control sample shows an absorption peak at 980 nm as expected for this 
type of nanotubes [126-128]. The conjugate gave a slight change in the peak (red shift 
effect) due to the protein attachment. The red shift can be attributed to a stronger 
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interaction of the hydrophobic part of the linker compared to that of the surfactant. 
Similar shifts have been observed for suspended SWNTs with protein [129] or DNA 
[130] adsorbed compared to those suspended with surfactant only. In order to determine 
the NT concentration for a particular sample, it was necessary to generate a calibration 
curve based on the optical density at 800 nm (Figure 21). 
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(a) 
 
(b) 
 
Figure 20: NIR absorbance spectra (normalized) for SWNTs with annexin V attached 
via the (a) FMOC linker or the (b) DSPE linker, and SWNTs only suspended using 
SDS (control).  
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Figure 21: Absorbance at 800 nm as function of SWNT concentration. SWNTs were 
suspended in 1 % SDS. 
 
The characterization of the SWNT-annexin V suspension by Raman 
spectroscopy (Figure 22) showed a characteristic spectrum for this type of SWNTs. All 
of the characteristic peaks were present, which means that the useful properties of the 
nanotubes were preserved.  
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Figure 22: Raman spectrum of the SWNT-annexin V conjugate, where the 
characteristic peak at 1590 cm-1 is visible. The conjugate was prepared using the FMOC 
linker. 
 
AFM analysis was used in evaluating the length of the carbon nanotubes after 
the sonication. The extended periods of sonication contributed directly for the 
shortening of the nanotubes. The results are summarized on Table 2. In Table 3, the 
detailed data for each sample is plotted in histograms, which allows to understand the 
distribution of sizes within the samples. 
 
Table 2: Mean length of SWNT after sonication for different time periods. 
 
 
 
 
Material Number of Measurements Mean Length 
(microns) 
1 hour sonication 40 2.4 
6 hour sonication 52 1.4 
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Table 3: Histogram distributions for the SWNTs length. This data was acquired from 
AFM images. 
1 h Sonication 6 h Sonication 
 
100.0% maximum 4.5 
50.0% median 2.1 
0.0% minimum 1.0 
 
Mean 2.4 
Std Dev 0.9 
Std Err Mean 0.1 
Upper 95% Mean 2.7 
Lower 95% Mean 2.1 
N 40 
 
 
100.0% maximum 2.7 
50.0% median 1.4 
0.0% minimum 0.7 
Mean 1.4 
Std Dev 0.4 
Std Err Mean 0.1 
Upper 95% Mean 1.6 
Lower 95% Mean 1.3 
N 51 
 
  
 The fact that the suspension of SWNTs was prepared using DMF instead of a 
surfactant, led to obtaining samples with low degree of nanotube isolation. This was an 
important factor that we attempted to avoid by trying to use a known surfactant, which 
would allow for obtaining a well dispersed suspension. However, the methods required 
to deposit the sample on the substrate were not compatible with any of the surfactants 
(SDS or sodium cholate). DMF is a solvent that is compatible with the deposition 
method (spin coating or evaporation) allowing for a successful deposition. The use of 
surfactants in an aqueous medium was not successful due to the fact that the angle of 
contact was too high and when combined with the fast spinning speed would not allow 
for the particle deposition to occur. There were therefore some repulsive effects 
between the suspension and the substrate. The use of a solvent allows to decrease the 
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angle of contact between the substrate and the sample. The evaporation method is also 
not recommended for aqueous suspensions due to the existence of high surface tension 
forces, which will induce the formation of bundles within the suspension.  
Even though this method is not giving data for the length of individual 
nanotubes but of nanotubes that are partially aggregated, the data in Table 3 for length 
is the same order of magnitude of the length reported for individual nanotubes by 
Southwest Nanotechnologies, which is 0.8 µm based on a few seconds of sonication 
[131].  Assuming the nanotubes in the AFM test are aggregating along their length, the 
individual length would be proportional to the length of aggregates.  Thus, for this 
assumption and according to the data in Table 3, the length of nanotubes after 6 h of 
sonication is 58%  of that after 1 h of sonication (= 100 x 1.4/2.4). 
 
Two-step Coupling of the Annexin V and SWNTs using EDC and NHS 
The coupling of annexin V with the SWNTs using the linker FMOC-NH-PEG-
NHS was successful. The protein and SWNTs concentrations obtained after conjugation 
are shown on Table 4. 
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Table 4: Protein and SWNTs concentrations after conjugation using the linker 
containing FMOC. The data shown is the average and the standard error of the mean for 
multiple runs (n=9). 
Linker [SWNTs] 
(mg/L) 
[Annexin 
V] (mg/L) 
SWNTs 
yield (%) 
Protein 
yield (%) 
Protein 
loading 
(mg/mg) 
FMOC 37.0 ± 7.3 176.2 ± 57.1 7.1 42.8 4.76 
 
The concentrations achieved were high enough to perform all of the in vitro 
studies. However, for in vivo studies in mice, the SWNT concentration shown in Table 
5 would give a dose of 0.28 mg/kg for the maximum injection volume of 150 µl and 
mouse weight of 20 g.  This is lower than was used for studies where the SWNTs were 
injected directly into the tumor (0.6-1.0 mg/kg) [89, 90] or into the bloodstream (3.6 
mg/kg) [91]. Due to this limitation, it was necessary to redesign the approach in order to 
increase the final concentration of the SWNTs, which would assure the desired dosage 
for in vivo administration. 
 
Conjugation of the DSPE-PEG-Maleimide linker with the SWNT-annexin V 
The conjugation of the SWNTs with the protein annexin V using the DSPE-
PEG-maleimide linker was also successful. This method was facilitated by the fact that 
annexin V contains only one cysteine residue that is five amino acids from the C-
terminus.  This cysteine is in a random coil configuration [16], so linking it to 
maleimide would not be expected to interfere with the binding of annexin V to PS 
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exposed on the surface of the tumor vasculature.  This protocol resulted in a substantial 
increase in both the SWNT and annexin V concentration as shown in Table 5.  
Therefore, this method was adopted for preparing SWNT-annexin V conjugates used in 
the in vitro and in vivo tests. 
 
Table 5: Protein and SWNT concentrations after conjugation using the linker 
containing DSPE. The data shown is the average and the standard error of the mean for 
multiple runs (n=9). 
Linker [SWNTs] 
(mg/L) 
[Annexin V] 
(mg/L) 
SWNTs 
yield (%) 
Protein 
yield (%) 
Protein 
loading 
(mg/mg) 
DSPE 202.0 ± 30.1 515.0 ± 107 25.3 30.8 2.55 
 
Visualization of the SWNT-annexin V Conjugates using Atomic Force Microscopy 
(AFM) 
The visualization of the SWNT-annexin V conjugates using AFM was 
successful, and the following image (Figure 23) shows a SWNT surrounded by the 
protein annexin V. The topographic image shows a color gradient that represents the 
height of the structures present on the sample, whereas the light areas correspond to tall 
structures and dark areas to low level features, respectively. The height distribution 
across the middle of the tube was determined using profile extraction through the 
Gwyddion software to be between 2.5 to 5.0 nm which is within the expected range 
seen in the literature for a protein bound to SWNTs [129]. In the study by Choi et al. 
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[132], there are two AFM images that display SWNTs deposited on a mica substrate. 
For those images, the height distribution profile was evaluated, and it was determined 
that the height of the SWNTs was 0.85 nm.  
 
 
Figure 23: AFM analysis. (a) Tapping mode AFM topography image of a SWNT-
annexin V conjugate and deposited on a mica substrate (scale bar = 50 nm). Lines 1 and 
2 correspond to cross-sections evaluated using the height profile function of the 
Gwyddion software. (b) Detailed AFM image showing a SWNT with the protein 
annexin V surrounding its surface. The SWNT is surrounded by the protein, which is 
represented with brighter pixels. (c) Cross-section height profiles for two different 
regions of the SWNT. The profile plotted with a black line corresponds to the cross-
section #1, while the red line represents the region defined by the cross-section #2. 
From the plot, the height of the protein was determined to be between 2.5 and 5.0 nm. 
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Visualization of Binding of SWNT-annexin V to Proliferating Endothelial Cells 
The labeling of the SWNT-annexin V conjugates with the FITC was successful, 
resulting in a fluorescent conjugate that emitted a bright green color when visualized 
under the fluorescent microscope. The stability of the dye allows for the detection of 
fluorescence for at least a week. 
The CellMask™ Plasma Membrane stain is a red stain that stained the cell 
membrane of each endothelial cell. The FITC was helpful to identify the SWNT-
annexin V conjugates on and within the cells. The need for determination of the exact 
location of the carbon nanotubes on or within the cell led us to visualize the samples 
with a confocal microscope. The confocal microscope analysis showed that the SWNT-
annexin V conjugates were present in several cells in the microscope field (Figure 24). 
Some cells showed a uniform distribution of the conjugates across the entire cell, while 
others had a well-defined distribution around the cell boundaries. The use of the 
different dyes allowed for the differentiation between the structures. 
 
 
Figure 24: Proliferating endothelial cells stained with the CellMask™ Plasma 
Membrane stain show the presence of FITC-labeled SWNT-annexin V conjugates 
bound to the surface. The image displays a plane located above the cell surface. The 
image results from the merging of the red channel with the green channel. Structures 
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represented with a yellow coloration correspond to structures that evidenced bright 
pixels for both color channels. Cells were incubated 2 h at 37 ºC with SWNT-annexin V 
at a concentration of 6 mg/L. The conjugates were previously prepared using the DSPE-
PEG-Mal linker. 
 
Laser Treatment of Endothelial Cells with SWNT-annexin V on the Cell Surface 
Before starting studying the effect of the conjugates when incubated in vitro 
with the endothelial cells, it was necessary to establish a safety limit where we could 
operate the laser without causing cytotoxicity to the cells. The maximum energy density 
had to be determined in order to evaluate the tolerance of the cells to this source of 
energy. As shown in Figure 25a, the highest allowed energy level without significant 
induction of cytotoxicity was 200 J/cm2. Increasing the waiting time between the 
irradiation and the Alamar blue assay did not contribute to significantly different cell 
viability (Figure 25b). 
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(a) 
 
(b) 
 
Figure 25: Assessment of the “safe region” to operate the laser system without the 
presence of cytotoxicity effects induced by the laser itself. Non-confluent endothelial 
cells were used. The laser irradiation times were 120 s for the 200 J/cm2 energy density 
and 130 s for the other energy densities. Data are presented as the mean ± SE (n=3). 
RFU stands for relative fluorescence units, and it correlates with the percent cell 
viability. (a) The Alamar Blue evaluation was started 1 h after the irradiation of the 
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cells. (b) A lower energy density range was used for this evaluation, which aimed to 
evaluate the difference between performing the Alamar Blue assay 1 h vs. 18 h after the 
irradiation.  
 
Cytotoxicity tests were performed in vitro on non-confluent endothelial cells 
with the laser energy density at 200 J/cm2.  Non-confluent cells were used since they 
actively express the PS molecules on the surface when growing in vitro, which does not 
happen when they reach a total confluence [133]. Since proliferating cells express PS 
naturally when grown in vitro there is no need to add H2O2 as a promoter of PS 
externalization. Because it was thought that shortening the SWNTs might make the i.v. 
injections easier in the in vivo tests, for the in vitro tests the SWNTs were prepared 
using the normal 1 h of sonication and also with the sonication time extended to 6 h.  
The results are shown in Figure 26.  Treatment with only the laser or only with either of 
the two SWNT preparations did not cause a significant change in cell viability 
compared to untreated cells.  When the cells were incubated with either SWNT 
preparation prior to laser treatment, compared to untreated cells the cell viability was 
reduced by 57% and 54% for SWNTs sonicated for 1 h and 6 h, respectively, which are 
statistically significant (p < 0.001).  The SWNTs sonicated for 1 h resulted in slightly 
more cytotoxicity than those sonicated for 6 h, but this difference was not statistically 
significant.     
Since the cells were washed thoroughly after incubation with the SWNT-
annexin V conjugate, it is clear that the cell death was caused by the SWNT-annexin V 
being bound to the endothelial cells and then being heated by the laser.  Earlier work in 
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this laboratory showed that a cytosine deaminase-annexin V fusion protein bound only 
on the surface of MDA-MB-231 breast cancer cells grown in vitro [133]; the specific 
binding of this fusion protein to these cells was relatively strong (Kd = 4 nM).  
Therefore, it is likely that the SWNT-annexin V conjugate, much larger than the 
cytosine deaminase-annexin V fusion protein, was also bound to the cell surface of the 
endothelial cells, and not internalized, in the tests with the laser.    
 
 
Figure 26: Effect on cell viability of incubation for 2 h of non-confluent endothelial 
cells with the SWNT-annexin V conjugate prepared with either 1 h or 6 h of sonication 
time.  The laser energy and power density were 200 J/cm2 and 1 W/cm2, respectively.  
Data are presented as the mean ± SE (n = 3), and statistical significance compared to 
untreated cells is denoted by * (p < 0.001). Cell viability was calculated by using data 
from Alamar blue assay. 
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Optical Pictures 
Optical pictures show human endothelial cells (HAAE-1) grown in vitro, before 
and after a laser treatment of cells that had been incubated with SWNT-annexin V 
(Figure 27). The elongated morphology of cells before treatment is characteristic of this 
type of cells. There is a difference in the cell morphology before and after the laser 
irradiation. The elongated shape is lost for the majority of the cells after laser 
irradiation, which suggests the occurrence of thermal ablation. 
 
  
BEFORE LASER TREATMENT AFTER LASER TREATMENT 
 
Figure 27: Optical pictures of human endothelial cells taken before and after a laser 
treatment of cells that had been incubated with SWNT-annexin V. The cells were in a 
non-confluent state. 
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Assessment of Sterility 
The sterilization of the SWNTs suspensions was successful resulting in the 
absence of visible colonies on the agar plates after incubation at 37 ºC. 
 
Effect of Sonication on the Optical Absorption of SWNTs 
Due to the fact that there was some difficulty injecting the SWNTs conjugates 
during the second in vivo study, it was necessary to evaluate if would be feasible to use 
shorter carbon nanotubes to facilitate the administration of those i.v.. It is possible that 
shorter nanotubes would lead to less clogging in the veins than the longer nanotubes 
upon injection. The shortening of the single-walled carbon nanotubes was attempted by 
performing extended sonication using different time intervals. From Figure 28 it is 
possible to conclude that there is a relationship between the sonication time used and 
the intensity of the absorption peak at 980 nm. The sonication time used is inversely 
proportional to the peak intensity at 980 nm. Also, the conjugation of the protein 
annexin V leads to a reduction on the peak intensity, which was not seen when 
sonication was for 1 h and the NTs were conjugated using the FMOC linker (Figure 20). 
Due to the diminishment on the peak intensity, it was decided not to use conjugates that 
were sonicated longer than 1 h. 
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Figure 28: UV-Vis-NIR absorbance spectra (normalized at 780 nm). This spectra 
compares five different suspensions prepared using SWNTs that were sonicated for 
different times (1, 6, 12 and 24 h). None of these suspensions were reacted with the 
protein annexin V, except for the last spectrum (6 h protein) that was sonicated for 6 h 
and then reacted with the protein annexin V using the DSPE-PEG-Mal linker.  
 
In vivo Studies  
During the safety test, some animals were irradiated at certain energy density 
levels in order to evaluate their response to the NIR irradiation. The results obtained are 
summarized on Table 6. 
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Table 6: Summary of the in vivo safety test. 
Number 
of 
animals 
Power density 
(W/cm
2
) 
Time (s) Energy density 
(J/cm
2
) 
Results 
2 1 400 400 Suggested pain during the 
procedure evidenced by 
animals moving while under 
the anesthetic effect. Tails 
were lifted after the irradiation 
session. 
No visible skin damage. 
Formation of black scars 
occurred within the 48 h after 
the irradiation. 
Revealed walking anomalies 
few days after irradiation. 
2 1 300 300 Suggested pain during the 
procedure evidenced by 
animals moving while under 
the anesthetic effect. Tails 
were lifted after the irradiation 
session. 
No visible skin damage. 
One of the animals was dead 
on the following day. 
Formation of black scars 
occurred within the 48 h after 
the irradiation. 
Revealed walking anomalies 
few days after irradiation. 
2 1 200 200 No visible skin damage. 
Formation of black scars 
occurred within the 48 h after 
the irradiation. 
Revealed walking anomalies 
few days after irradiation. 
2 1 175 175 No visible skin damage. 
Formation of black scars 
occurred within the 48 h after 
the irradiation.  
Irradiation level was well 
tolerated by the animals. 
1 1 120 120 No visible skin damage. 
Formation of black scars 
occurred within the 48 h after 
the irradiation. 
Irradiation level was well 
tolerated by the animals. 
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It was found that when the SWNT-annexin V conjugate that was prepared using 
1 h sonication was centrifuged just before injection, the suspension flowed out of the 
tail vein when injected. Thus, the difficulty associated with the injection was likely due 
to aggregates developing while the conjugate was stored at 4oC. Therefore, the SWNTs 
were prepared using a 1 h sonication time, and the suspension containing the conjugate 
was centrifuged just before being injected in the tail vein.   
 Besides having a group of mice treated with injection of the SWNT-annexin V 
conjugate followed the next day by laser treatment, a group was added that had the 
SWNT-annexin V and laser treatment with the addition of an injection of 
cyclophosphamide at a low dose (50 mg/kg) 48 h before the laser treatment. Low dose 
treatment with CY has led to increasing antitumor immunity in mouse models, which is 
believed to be caused by selective depletion of T-regulatory cells. In one study, high 
cure rates in mice with a reticulum cell sarcoma were achieved with treatment with low 
dose CY and photodynamic therapy [116]. T-regulatory cells protect the body from 
autoimmune disease by suppressing self-reactive T cells and may also block antitumor 
immune responses mediated by tumor-specific T cells. 
 The in vivo test results for BALB/cJ mice with 4T1 mouse mammary tumor 
implants are shown in Figure 29. Using a tagging system, changes in each animal could 
be monitored. The tumor sizes in the two groups treated with the laser (SWNTs+Laser 
and CY+SWNTs+Laser) are significantly lower than those in the untreated group from 
16 days after cell inoculation (p < 0.01). After the laser treatment, the tumors in the two 
groups treated with SWNTs steadily reduced in size, and 11 days later (at day 26) there 
were no animals with visible tumors in the SWNTs+Laser and SWNTs+Laser+CY 
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groups. A few days later, in three animals (two from the SWNTs+Laser and one from 
the SWNTs+Laser+CY groups) the reoccurrence of palpable tumors was detected. 
These tumors were growing outside of the area treated with the laser, so it is believed 
that they did not receive a full treatment. It was decided to re-treat these three animals at 
day 37, by repeating the same protocol previously used on days 13 through 15. Before 
that day, one of the animals in the SWNTs + laser group died, possibly due to the high 
degree of metastasis. During the irradiation conducted on day 37, the other animal from 
the SWNTs + laser group also died. It is suspected that the animal was too weak to 
resist the irradiation session. The only animal that was treated ended up dying on day 46 
with an average tumor volume of 415 mm3. It is likely that this animal died because of 
metastasis, not because of the size of the tumor. Figure 31 illustrates the difference in 
appearance between an animal from the untreated group and another animal from one of 
treatment groups. 
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Figure 29: Treatment of BALB/cJ mice with implanted 4T1 mouse mammary tumors.  
The doses injected i.p. were 50 mg/kg cyclophosphamide (CY) and 0.82 mg SWNT/kg 
(109.1 SWNT mg/L, 150 µL).  The laser energy and power density were 175 J/cm2 and 
1 W/cm2 (time = 175 s). Data are presented as the mean ± SE (n = 6), and statistical 
significance compared to untreated cells is denoted by * (p < 0.01). 
 
The in vivo study was conducted for 60 days since the inoculation of the cancer 
cells into the animals. The majority of the animals stayed alive until day 38 as shown in 
the survival curve (Figure 30). Some of the animals died naturally, while some of them 
were euthanized based on the presence of signs of possible discomfort. It is important to 
mention that the animals from the CY+SWNTs+Laser had the better survival rate from 
*       *       *       *      *      *       *       *      *  * 
 * 
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the study. One animal had a significantly longer longevity being alive until day 59, 
which corresponds to a survival of 44 days post-irradiation. 
 
 
Figure 30: Survival curve for the in vivo study. Euthanasia was performed on any 
animal that showed signs of discomfort. The first animal that died was from the 
untreated group and that death occurred on day 34. On day 39 and while performing the 
second irradiation session, one of the animals present in the SWNTs+Laser group did 
not survive.  On this day, the remaining animals from the Untreated group and one 
animal from the Laser group were sacrificed. By day 42 all of the animals from 
SWNTs+Laser were dead. There was one animal in the CY+SWNTs+Laser group that 
had a significantly longer longevity, being alive until day 59, which corresponds to a 
survival of 44 days post-irradiation. 
 
After euthanizing the animals, a total of six animals were chosen for further 
evaluation, two from each of the untreated group, SWNTs + laser group, SWNTs + 
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laser + CY group. For the latter two groups, mice with no visible tumors were chosen.  
The tumors, lungs, and livers were dissected out and preserved in 10% formalin. The 
number of metastatic nodules was counted in the lungs, and the results are shown in 
Table 7. The number of these nodules in the lungs was negligible for 2 animals from the 
SWNTs+Laser group and for one animal from the CY+SWNTs+Laser. One of the 
animals from the CY+SWNTs+Laser that was dissected exhibited a relatively small 
number of visible nodules. It is therefore likely that there were already metastases to the 
lungs for some animals when the laser treatment was carried out at 15 days from the 
injection of tumor cells. The injection of CY in conjunction with laser + SWNT 
treatment, intended to boost the immune response to the tumor, did not lead to fewer 
metastatic nodules, compared to laser + SWNT treatment alone.     
 
  
(a) (b) 
 
Figure 31: Pictures of two mice from the in vivo study. (a) Animal treated with the 
SWNT-annexin V conjugate and NIR irradiation. The tumor completely regressed after 
therapy. (b) Animal from the untreated group where there was no tumor regression. 
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Table 7: Metastatic nodules evaluation. 
ANIMAL # GROUP 
No. OF VISIBLE 
NODULES 
1 Untreated 16 
 
4 Untreated 18 
 
19 SWNTs + Laser 0 
 
21 SWNTs + Laser 0 
 
31 Cy + SWNTs + Laser 0 
 
32 Cy + SWNTs + Laser 4 
 
 
The majority of the animals from the treatment groups (SWNTs+Laser and 
CY+SWNTs+Laser) completely regenerated the epithelial layer on the irradiation site, 
with absence of the black scar and fur regrowth. This visual observation correlated with 
the histological analysis as shown in the Table 8. The specimens were sent for 
histological analysis by the OU Health Sciences Center. The qualitative analysis is 
shown on Figure 32 and Table 8.  
The animals from the untreated group presented multiple micro- and 
macrometastases in the lungs and liver. There was also the evidence of neutrophils in 
the liver, which is suggestive of a leukomoid response and may be strain-related. The 
normal tissue in the lungs was almost absent. The tumor masses presented extensive 
ischemic necrotic areas, with the presence of an abnormal epithelial cell layer. 
On other side, three animals of the treatment group were completely free of 
metastases, presenting intact morphology in the lungs and liver. The samples collected 
from the tumoral sites evidenced an epithelial layer with an intact and preserved 
morphology, without evidence of tumoral cells. However, one of the animals from the 
CY+SWNTs+Laser had metastases present in the lungs and liver. This result shows the 
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variability among the organisms, which can possibly be explained by having metastases 
forming prior to the treatment start. The original tumoral site had the same appearance 
as the other animals from the treatment group, i.e., absence of any evidence of tumor 
cells.  
  
(a) (b) 
  
(c) (d) 
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(e) (f) 
Figure 32: Histological images for different specimens collected from one of the 
animals from the untreated group (a-d) and treated group (e-f). (a) Sectional image of a 
portion of the liver (40 X) with evidence of metastases present on the left side of the 
black asterisk. (b) Sectional image of the liver (40 X) with multiple perivascular focal 
aggregates consisting mostly of neutrophils evidenced on the left side of the black 
asterisks. (c) Sectional image of the tumor (40 X) illustrating a large necrotic mass 
denoted by the black asterisk. The region that surrounds the black + symbol presents a 
large number of atypical cells that were viable. (d) Sectional image of a portion of the 
lung (40 X) with evidence of metastases in the blood vessel (denoted by the black 
asterisk) and also in the periphery. (e) Sectional image of a portion of the skin (10 X), 
collected from the original tumor site, showing an intact epithelial layer without the 
presence of any atypical cells. (f) Sectional image of a portion of the lung (20 X) 
displaying a normal morphology with very distinct alveolar sacs. 
 
 
 
Table 8: Histological analysis obtained for specimens collected from six animals. 
Animal # Group Lungs Liver Tumor 
1 Untreated Multiple macroscopic metastases 
present on the surface; evidence of 
invasion of the chest tissue. Almost 
complete absence of normal tissue. 
Multiple perivascular locations contained 
a focal aggregate consisting mostly of 
neutrophils. This is suggestive of a 
leukomoid response and may be strain-
related. Numerous microscopic 
metastases found in the sinusoids. Almost 
complete absence of normal tissue. 
Extensive ischemic necrosis in the mass. It 
was comprised of mostly atypical-appearing 
cells ranging from oval to spindle-shaped 
4 Untreated High degree of macroscopic 
metastases, with extensive metastatic 
foci. Almost complete absence of 
normal tissue. 
Multiple perivascular locations contained 
a focal aggregate consisting mostly of 
neutrophils. This is suggestive of a 
leukomoid response and may be strain-
related. The area occupied by the 
micrometastases was lower than the 
animal #1 and not so severe. Almost 
complete absence of normal tissue. 
About 66 % of the mass appeared to be 
necrotic, probably as result of ischemia. 
Epithelial cell layer was not viable. 
19 SWNTs + 
Laser 
Intact morphology and free of 
metastases. 
Intact morphology and free of metastases. No evidence of the original tumor. 
Epithelial layer presents an intact 
morphology. 
21 SWNTs + 
Laser 
Intact morphology and free of 
metastases. 
Intact morphology and free of metastases. No evidence of the original tumor. 
Epithelial layer presents an intact 
morphology. 
31 CY + 
SWNTs + 
Laser 
Intact morphology and free of 
metastases. 
Intact morphology and free of metastases. No evidence of the original tumor. 
Epithelial layer presents an intact 
morphology. 
32 CY + 
SWNTs + 
Laser 
Presence of some metastases. The incidence of intrasinusoidal atypical 
cells, suggestive of micrometastasis was 
lower than the animals from the 
Untreated group. 
No evidence of the original tumor. 
Epithelial layer presents an intact 
morphology. 
                  92 
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As seen from the histological analyses, there were metastases present in the 
lungs for some of the animals which is the most suggested cause of death. From a 
literature analysis, 4T1 cells are known for being poorly immunogenic and highly 
metastatic inducing metastases even before the tumors are palpable for this particular 
animal strain [134, 135]. It has been also reported that even if there is complete tumor 
eradication the most common cause of death is lung failure because of tumor 
metastases. 
These results are very encouraging since we were able to eradicate the tumors in 
a large fraction of the animals in the treatment groups. Currently there are only two 
research studies that use a similar approach in terms of using SWNTs administered i.v. 
for cancer treatment [91, 128]. Both studies used Balb/c mice and the 4T1 cell line.  
Robinson et al. [91] used SWNTs conjugated with PEGylated phospholipids at a 
dosage of 3.6 mg/kg. Those were injected i.v. 5 days after cell inoculation, and 
irradiation at 808 nm followed 3 days later (180 J/cm2). The tumor average size when 
performing the treatment was equal to 22 mm3, which is approximately five times 
smaller than the size our animals had when subjected to the irradiation. Their study was 
successful in terms of reaching complete tumor eradication for all of the animals in the 
treatment group with no tumor reoccurrences for over 6 months. 
Liu et al. [128] using the same administration mode used a higher energy density 
(300 J/cm2) and performed laser irradiation at 808 nm 48 h after nanotube 
administration (dosage not given). The conjugates used were composed of SWNTs with 
amphiphilic polymers anchored to the surface through an intermediate PEG molecule. 
Temperature rises were reported in the order of 50 ºC for the animals that were part of 
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the treatment group versus 1-2 ºC temperature increase for the control groups. Their 
study was not so impressive as the one by Robinson et al. since they were not able to 
completely eradicate the tumors for more than 2 weeks. In fact, two out of seven 
animals only evidenced a reduction on the growth rate, while the other five totally 
regressed for at least one week, but reoccurred after that time period. 
Compared to the in vivo studies by Robinson et al. and Liu et al., it is seen that 
the laser energy density used in our study was similar.  The SWNT dose in our study 
was more than four times lower than in the Robinson et al. study and yet still achieved a 
high degree of tumor eradication when combined with laser treatment; this is likely 
because we targeted the SWNTs to the tumor vasculature via annexin V so that SWNTs 
selectively accumulate in the tumor, instead of being distributed throughout the body.  
In neither of these other studies were the SWNTs targeted, which could lead to the 
undesirable side effect of thermal ablation of normal tissue.             
 
Biodistribution Study 
Two animals were injected with the SWNT conjugates during the biodistribution 
study. A standard curve of the Raman G band intensity as a function of SWNT 
concentration is shown in the Appendix T. The Raman spectrum of a SWNT suspension 
with a known nanotube concentration is illustrated in Figure 33. 
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Figure 33: Raman spectrum for a SWNT suspension with a nanotube concentration of 
98.6 mg/L. A drop of the sample (previously diluted using a 1 % SDS solution) was 
allowed to dry. The signal was acquired using 64 scans in a FT-Raman system. 
 
While attempting to evaluate the presence of SWNTs in the tissue samples, 
different acquisition modes and settings were used in order to optimize the ability to 
detect those structures. The optimal settings used corresponded to 64 scans / sample and 
by having a drop placed on top a Ge disk (previously allowed to dry at room 
temperature). The sample was carefully placed in front of the laser beam. 
The majority of the tissues collected from the two animals that were used for the 
biodistribution did exhibit a characteristic G band at 1,590 cm-1 as expected. Each 
Raman spectrum obtained from those samples exhibited the presence of a characteristic 
G band associated to the SWNTs. An example of a spectrum obtained for one of the 
samples is illustrated in Figure 34. The spectrum exhibits a characteristic G band, 
therefore meaning the presence of single-walled carbon nanotubes in the samples. The 
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percent injected dose (% ID) was determined for each tissue sample by using the 
following equation: 
 
(adapted from [124]). 
 
 
Figure 34: Raman spectrum acquired for a liver tissue sample. The sample was 
previously deposited on the surface of a Ge metallic disk and allowed to dry at room 
temperature for 30 minutes. The laser light was then shined directly into the sample in a 
FT-Raman system.  
 
The data for % ID and % ID/g of tissue is plotted in Figure 35.  The tumors had 
a higher total SWNT accumulation followed by the livers, with much lower 
accumulation in the kidneys (Figure 35A). From the six samples evaluated, the only one 
that did not have a detectable amount of SWNTs (i.e., no Raman peak) was in a kidney, 
which is probably because the clearance rate is relatively low at 24 hours post 
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administration and also because there could be variable excretion from animal to 
animal.  
A biodistribution study conducted by Liu et al. [124] reported that for a similar 
administration level (≈ 0.98 mg/kg) there was no Raman signal registered for the 
majority of the organs. Liu et al. used SWNTs conjugated with DSPE-PEG (with 
different PEG molecular weights) reporting a minor Raman signal for the kidneys and a 
strong signal for the livers 24 hours after SWNT administration (with an approximately 
70 % ID/g for the conjugates that had a PEG with a M.W. = 2,000 Da). In our study, the 
average % ID/g for the livers and the kidneys was approximately equal to 6 %/g and 3 
%/g, respectively. Therefore, the concentration of SWNTs in the liver in the Liu et al. 
study was much higher than in our study, even though the SWNT administration level 
was similar. It is important to note that the length of the carbon nanotubes used in the 
Liu et al. study was approximately eight times smaller than the nanotubes used in this 
project, and therefore possibly explaining the higher accumulation in the liver within 
the same time interval. The successful detection of those nanostructures occurred when 
the administration dosage was approximately six times higher than that used in our 
study. 
In the study by Robinson et al. [91] where non-targeted, PEGylated SWNTs 
were injected i.v. at 3.6 mg/kg in mice with 4T1 breast tumors, the concentration of 
SWNTs was 55 % ID/g and 8 % ID/g after 48 hours in the liver and tumor, respectively. 
Thus, the concentration of SWNTs in the Robinson et al. study was much greater in the 
liver than in our study (about nine times higher) but was similar in the tumor to our 
study. 
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(a) 
 
(b) 
 
Figure 35: Biodistribution of SWNT-annexin V 24 hours post administration evaluated 
by FT-Raman spectroscopy. (a) % ID stands for percent of injected dose. (b) % ID/g 
stands for percent injected dose per gram of tissue. The data was averaged and the 
standard error of the mean was determined (n=2). 
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Conclusions and Future Studies 
 
The present study aims the enhancement of the current and conventional 
therapeutic approaches to treat neoplasms. The need for more efficient therapies with a 
higher success rate and a lowering of side effects makes this research project suitable to 
overcome the current limitations associated with the current treatments. Radio- and 
chemotherapy along with invasive procedures have been used in current therapeutical 
procedures for a long time period and their limitations are well known. Based on the 
hypotheses that define this project, it is foreseen that this research will bring 
improvements to the actual therapies.  
The production of the protein annexin V using recombinant technology allowed 
for its production in our laboratory which was beneficial in terms of saving time and 
even more important reducing costs. Also, the ability to have easy access to the 
nanotube samples was a key component in terms of obtaining nanotube suspensions 
with the highest purity levels that can be currently obtained. The theory behind the use 
of carbon nanotubes to the treatment of cancer is not new however, the targeting of 
cancer cells combined with the excellent properties inherent to the nanostructures is 
something new that distinguishes this research work from other studies that have been 
published in the last couple of years. The in vitro studies revealed interesting results that 
helped us design the in vivo studies as an approach to confirm this theory in live 
organisms.  
The binding ability for the protein annexin V when incubated in vitro with non-
confluent endothelial cells was strong, and the dissociation constant value was within 
the expected range as seen in the literature. Therefore, hypotheses 1 and 2, which 
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concerned producing annexin V in a soluble and functional form that binds selectively 
to endothelial cells, were proven.  
The use of two different conjugation protocols allowed for obtaining single 
walled carbon nanotubes with immobilized annexin V at concentrations that were high 
enough to perform in vitro laser irradiation. The need for higher dosage levels of the 
conjugates used for the in vivo administration led to the need of developing a new 
conjugation protocol which allowed for the immobilization of higher amounts of protein 
on the surface of the nanostructures. The SWNT-annexin V conjugate prepared using 
the linker that contains DSPE gave a relatively high concentration of SWNTs in 
suspension (202 mg/L).  The SWNT-annexin V conjugate gave a significantly peak of 
optical absorption near 980 nm that was similar in intensity and wavelength to when 
SWNTs were not conjugated to annexin V, which validates hypothesis 3. 
A short incubation of endothelial cells with this conjugate followed by laser 
treatment resulted in significant thermal ablation. The nanotubes or the laser by 
themselves did not induce cell cytotoxicity, as expected.  
The in vivo studies were successful in terms of inducing tumor regression within 
the animals in the treatment groups. One day after the laser irradiation of the animals, 
there was already a significant difference in the average tumor volumes between the 
animals from the treatment group and the untreated animals. At one point after laser 
treatment in the two treatment groups, there were no animals with visible tumors; later 
in a few animals there was tumor regrowth outside the area of the laser beam. It is 
important to mention that there was black scar formation specifically on the area where 
the tumor was; however there was no visible scar on the surrounding area, which was 
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also subjected to irradiation. Another important finding is that the skin epithelial layer 
in the area of the tumor was completely regenerated, with the absence of the black scar 
and tumor regrowth for the majority of the animals in the group treated with SWNTs 
and the laser. The biodistribution study revealed that there was a SWNT accumulation 
in the tumor (verifying the predicted accumulation as stated in the hypothesis 4), liver, 
and kidney 24 hours post administration. Compared to a study by another group that 
used non-targeted SWNTs and laser treatment of the same tumors in mice (Robinson et 
al. [91]), tumor eradication was achieved in this study using a much lower dosage of 
SWNTs (approximately four times lower) while resulting in a similar concentration of 
SWNTs in the tumor. 
It is possible to conclude that this therapeutic approach was successful in terms 
of achieving partial or complete tumor eradication for the treatment groups, thus 
confirming hypothesis 4. Also, it is very significant that the epithelial cell layer was 
intact as observed by the histology analysis in the epithelial area where previously there 
were tumors in the mice examined in both treatment groups. In addition, the dark scars 
where the tumors were treated in both treatment groups had returned to a normal skin 
color by the end of the study for the majority of the animals. 
The addition of CY did not translate into a significant difference in terms of 
tumor volume reduction; however, there was an increased survival of animals in the 
treatment group that received CY compared to the treatment group that did not, then 
partially proving hypothesis 5. This difference in survival could not be correlated with 
the histology studies of the tumor, lungs, and liver. 
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The results obtained on this study are encouraging, and it is suggested to pursue 
some additional approaches in future studies that will enhance the efficacy of the 
current proposed therapy.  
1. In order to enhance the externalization of the PS molecules on the surface of 
the endothelial cells that line the tumor vasculature, it is suggested the 
administration of docetaxel–a well-known chemotherapeutic drug–at 
subtoxic dosages. Huang et al. [136] proved that the administration of this 
drug at those dosages was responsible for significant more externalization of 
anionic phospholipids in vivo. 
2. In order to attempt to mount a more efficient immune response against the 
tumor antigens, it is proposed to explore the possibility of using alternative 
immunostimulants, both single or in combination. The cytotoxic T 
lymphocyte-associated antigens 4 (CTLA-4) are involved with the process 
of downregulation of the immune system by decreasing or suppressing the 
activation of T-cells. Blocking these antigens (using a CTLA-4 blockade) 
can be useful to mount an immune response against possible tumor antigens 
presented to the immune system [134, 137]. Glycated chitosan (GC) is 
another compound that can be obtained by linking galactose molecules to 
chitosan molecules. GC has been used in combination with laser 
phototherapies for cancer treatment and it is known to have 
immunostimulatory properties [138, 139]. In the study by Zhou et al., the 
GC when combined with a laser phototherapy had the ability to increase the 
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secretion of TNFα, which is an effector cytokine produced by mouse 
macrophages. 
3. Tracking any changes within the tumor region is important and beneficial in 
order to determine if further irradiation therapy is necessary to achieve 
complete tumor eradication. This can be accomplished by using a tumor 
transfected with red fluorescent protein (RFP) that will allow to visualize the 
tumor region using a small animal imaging system [140]. Another 
alternative would be to use a small PET-CT imaging system [141]. After 
performing the first irradiation session and waiting 48 h, it would be 
recommended to perform a visual evaluation in order to check for the need 
of additional irradiation sessions. 
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APPENDIX A 
 
Laboratory Protocols 
 
A.1. Laboratory Protocols 
 
A.1.1. Luria Bertani (LB) medium 
 
Table A.1: LB medium composition [142]. 
Component Amount 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 5 g 
1N NaOH 1 ml 
Add dH2O to 1.0 L and autoclave (25 mins). 
 
A.1.2. LB agar 
 
Table A.2: LB Agar / SOC medium composition (per Liter). 
Component Amount 
Tryptone 10 g 
Yeast extract 5 g 
NaCl  5 g 
Agar 15 g 
Add dH2O to 1.0 L 
Adjust pH to 7.0 with 5 N NaOH 
Autoclave 
Pour into Petri dishes 
         (~25 ml/100-mm plate) 
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A.1.3. Additives: 
 
Antibiotic: Kanamycin (C18H36N4O11∙H2SO4) 
Galactosides: IPTG to 0.1 mM 
 
Table A.3: Kanamycin properties [142]. 
Antibiotic a Stock conc. 
(mg/ml) 
Final conc. 
(µg/ml) 
Mode of 
action 
Mode of resistance 
Kanamycin 10 30 Bactericidal; 
inhibits 
protein 
synthesis; 
inhibits 
translocation 
and elicits 
miscoding. 
Aminoglycoside 
phosphotransferase 
also known as 
neomycin 
phosphotransferase, 
aminoglycoside 
acetyltransferase, and 
aminoglycoside 
nucleotidyltransferase; 
inactivates 
kanamycin. 
a Kanamycin should be stored at 4 ºC, since it loses potency at room temperature [142]. 
 
A.1.4. Kanamycin preparation 
 
To prepare kanamycin (10 mg/ml) 25 ml of deionized water and 250 mg of kanamycin 
(Sigma, St. Louis, MO) were mixed, and stored in the freezer (-20 ºC). 
 
A.1.5. IPTG preparation (10 mg/ml) 
 
0.4 g of IPTG (stored at -20 ºC) 
40 ml of sterile and distilled water 
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A.1.6. Sonication buffer preparation 
 
0.05 mM N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK) 
1 mM phenylmethylsulfonyl fluoride (PMSF) 
1 % of ethanol (ethyl alcohol) 
0.01 % β-mercaptoethanol 
0.02 M of sodium phosphate 
 
The pH was adjusted to 7.4. 
 
A.1.7. Sonication protocol (4 ºC) 
 
The sonication equipment (Sonic Dismembrator 550 (Fisher Scientific, USA)) is 
turned on to the position 4/5 (power of 76.5 W). The tip of the sonicator (Sonic 
Dismembrator 550 (Fisher Scientific, USA)) is immersed in the solution to disrupt the 
cell membranes for 30 seconds. After that, the sonicator is turned off for another 30 
seconds (with the beaker placed on ice). This procedure is repeated 4x corresponding to 
a total sonication time of 2.5 minutes. After the sonication, the solution is centrifuged at 
12,000 x g for 30 min. 
 
 
Figure A.1.1.: Sonication process. 
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A.1.8. HRV 3C protease 
 
Recombinant type 14 3C protease from human rhinovirus (HRV 3C) is a recombinant 
restriction-grade protease. HRV 3C is a highly purified recombinant 6X His-fusion 
protein, that recognizes the same cleavage site as the native enzyme: Leu Glu Val Leu 
Phe Gln ↓ Gly Pro. The small, 22-kDa size of the protease, optimal activity at 4 ºC, high 
specificity, and His∙Tag® fusion make HRV 3C protease an ideal choice for rapid 
removal of fusion tags [143]. 
 
Components 
 
• 500 U  HRV 3C Protease (2000 U/ml in 150 mM NaCl, 50 mM Tris-
HCl, 1 mM EDTA, 0.5 mM THP, 50% glycerol, pH 8.0) 
• 10 μg  HRV 3C Cleavage Control Protein (in 100 mM NaCl, 50 mM 
Tris-HCl, 10 mM EDTA, 50% glycerol, pH 7.4) 
• 10 ml  10X HRV 3C Protease Cleavage Buffer (1.5 M NaCl, 0.5 M Tris-
HCl, pH 7.5) 
 
Unit definition: One unit will cleave > 95 % of 100 µg His∙Tag fusion control protein in 
50 mM Tris-HCl, 150 mM NaCl, pH 7.5 at 4 ºC for 16 hours. 
 
A.1.9. Tris-HCl 
 
1.5 M Tris-HCl pH 8.8 (TRIS – Electrophoresis purity reagent (Tris(hydroxymethyl)-
aminomethane) (CA, USA)) 
1 M Tris-HCl pH 6.8 (TRIS – Electrophoresis purity reagent (Tris(hydroxymethyl)-
aminomethane) (CA, USA)) 
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A.1.10. Acrylamide (29%) Bis (1%) 
 
Mix 29.0 g acrylamide and 1.0 g N-N’-methylene-bisacrylamide in a total volume of 
100 ml H2O. Store at 4 ºC in the dark. Discard after 30 days, since acrylamide gradually 
hydrolyzes to acrylic acid and ammonia. 
CAUTION: Acrylamide monomer is neurotoxic. Gloves should be worn while handling 
the solution, and the solution should not be pipetted by mouth. 
 
A.1.11. Electrophoresis buffer 
 
10% Bio-Rad 10x Tris/Glycine/SDS Buffer (Bio-Rad Laboratories (Hercules, CA)) 
90% H2O 
 
A.1.12. Ammonium persulfate preparation 
 
10 g ammonium persulfate 
H2O to 100 ml total volume 
Store refrigerated ~ 2 weeks. 
 
A.1.13. Cell Medium Preparation 
 
In order to prepare a new bottle of cell medium for the human endothelial cells mix the 
following: 
- F12K medium (1 flask, 500 ml); 
- 50 ml of fetal bovine serum; 
- 5 ml of antibiotic (penicillin and streptomycin); 
- 3 ml of heparin (0.1 mg/ml) and, 
- 1.5 ml of ECGS (endothelial cell growth supplement; 0.03 mg/ml). 
 
For the 4T1 cells mix the following: 
- RPMI-1640 medium (1 flask, 500 ml); 
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- 50 ml of fetal bovine serum; 
- 5 ml of antibiotic (penicillin and streptomycin). 
 
Due to the fact that the medium contains proteins, it can be stored only for 
approximately 2-3 weeks at 4 ºC. 
 
A.1.14. PBS preparation 
 
Mix: 
8 g of NaCl  
0.2 g of KCl 
1.44 g of Na2HPO4 
0.24 g of KH2PO4 
1 L of deionized water. 
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A.2 Experimental Protocols 
 
A.2.1. Transformation Protocol 
 
Transformation 
NovaBlue GigaSingles™ Competent Cells (Cat. No. 71127) are provided in the Ek/LIC 
vector kits and should be used for initial cloning with all Ek/LIC Vectors. NovaBlue is a 
convenient host for initial cloning of target DNA into the Ek/LIC vector due to its high 
transformation efficiency and the high yields and excellent plasmid DNA that results 
from recA endA mutations. Single-use NovaBlue GigaSingles Competent Cells are 
provided in 50 μl aliquots. The pET, pCDF-2, pRSF-2, and pTriEx™ Ek/LIC vector 
kits also receive expression host strains in standard, 0.2 ml aliquots. 
The standard transformation reaction calls for 20 μl of cells, so each tube contains 
enough cells for 10 transformations. The following protocol is appropriate for 
transformations using either GigaSingles or Standard Competent Cells with noted 
differences for the steps effected. 
 
Note: Upon receipt of competent cells from Novagen, verify that the cells are frozen and 
that dry ice is present in the shipping container. Immediately place the competent cells 
at –70 °C or below. For optimal results, do not allow the cells to thaw at any time prior 
to use. Handle only the very top of the tube and the tube cap to prevent the cells from 
warming. Keep the cells on ice whenever possible. To mix cells, flick the tube 1–3 times. 
NEVER vortex competent cells. 
 
1. Remove the appropriate number of competent cell tubes from the freezer (include on 
extra sample for the Test Plasmid positive control, if desired). Immediately place the 
tubes on ice, so that all but the cap is immersed in ice. Allow the cells to thaw on ice for 
2–5 min. 
2. Visually examine the cells and gently flick the cells 1–2 times to evenly resuspend 
the cells. 
3. GigaSingles Kits: 
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If a Test Plasmid sample is included, proceed to Step 4, if not go directly to 
Step 5. 
Standard Kits: 
Place the required number of 1.5 ml snapcap polypropylene tubes on ice to pre-chill. 
Pipet 20 μl aliquots of cells into the prechilled tubes. 
4. (Optional) To determine transformation efficiency, add 1 μl (0.2 ng) Test Plasmid to 
one of the tubes containing cells. Gently flick the tube to mix and return to the ice. 
5. Add 1 μl of the annealing reaction directly to the cells. Stir gently to mix and return 
to the ice. 
Repeat for additional samples. 
6. Incubate on ice for 5 min. 
7. Heat the tubes for exactly 30 s in a 42 °C water bath; do not shake. 
8. Place the tubes on ice for 2 min. 
9. GigaSingles Kits: 
Add 250 μl of room temperature SOC 
medium to each tube. Keep the tubes on 
ice until all have received SOC. 
 
Standard Kits: 
Add 80 μl of room temperature SOC medium to 
each tube. Keep the tubes on ice until all have 
received SOC. 
 
10. Incubate at 37 °C while shaking at 250 rpm for 60 min prior to plating on selective 
medium. 
11. Selection for transformants is accomplished by plating on medium containing 
antibiotic for the plasmid encoded drug resistance (50 μg/ml carbenicillin or ampicillin 
for the Amp resistance marker, 30 μg/ml kanamycin for the kan resistance marker, and 
50 μg/ml of streptomycin and/or spectinomycin for the aadA gene). Additional host-
specific antibiotics may also be appropriate to ensure maintenance of the host-encoded 
feature(s). 
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When plating less than 25 μl, first pipet a “pool” of SOC onto the plate and then pipet 
the cells into the SOC. The appropriate amount of transformation mixture to plate varies 
with the efficiencies of the annealing process and of the competent cells (see certificate 
of analysis for efficiency). For recombinants in NovaBlue, expect 105–107 
transformants/μg plasmid, depending on the particular insert and the ligation efficiency. 
For the Test Plasmid, plate only 5 μl of the NovaBlue transformation mix or 10 μl of 
any strain with a 2 × 106 efficiency in a “pool” of SOC on an LB agar plate containing 
50 μg/ml carbenicillin or ampicillin (because the Test Plasmid carries the ampicillin 
resistance gene, bla). 
12. Set plates on the bench for several minutes to allow excess liquid to be absorbed, 
and then invert and incubate overnight at 37 °C. 
 
Transformation Protocol for Experienced Users 
Note: See the next section for a detailed protocol. 
1. Thaw the required number of tubes of cells on ice and mix gently to ensure that the 
cells are evenly suspended. 
2. Standard Kits: 
Place the required number of 1.5 ml polypropylene microcentrifuge 
tubes on ice to pre-chill. Pipet 20 μl aliquots of cells into the pre-chilled tubes. 
Singles™ Kits: 
Proceed to Step 3. 
3. Add 1 μl of the DNA solution directly to the cells. Stir gently to mix. 
4. Place the tubes on ice for 5 min. 
5. Heat the tubes for exactly 30 s in a 42 °C water bath; do not shake. 
6. Place on ice for 2 min. 
7. Standard Kits: 
Add 80 μl of room temperature SOC medium to each tube. 
Singles Kits: 
Add 250 μl of room temperature SOC medium to each tube. 
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8. Selection for transformants is accomplished by plating on medium containing 
antibiotic for the plasmid-encoded drug resistance. Additional host-specific antibiotics 
may also be appropriate to insure maintenance of the host-encoded feature(s). 
When using NovaBlue strain: if selecting for ampicillin or chloramphenicol 
resistance, plate 5–50 μl cells directly on selective medium (plus IPTG/X-gal for 
plasmids that permit blue/white screening). If selecting for kanamycin or 
streptomycin/spectinomycin resistance, shake at 37 °C (250 rpm) for 30 min prior to 
plating on selective medium. 
When using strains other than NovaBlue, incubate at 37 °C while shaking at 250 rpm 
for 60 min prior to plating on selective medium. 
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A.2.2. Bradford protein assay 
 
Principle 
 
This assay is a dye-binding assay in which a differential color change of dye occurs in 
response to various concentrations of protein. The Coomassie blue dye binds to 
primarily basic and aromatic amino acid residues, especially arginine. 
 
Materials 
 
1x dye reagent (Bio-Rad, Hercules, CA, USA) and the standard were acquired from 
Biorad. A Shimadzu UV-2101 PC UV-Vis spectrophotometer (Shimadzu, Japan) 
spectrophotometer was used to measure the absorbance. 
 
Protocol 
 
1. Remove the 1x dye reagent from 4 ºC storage and let it warm to ambient 
temperature. Invert the 1x dye reagent a few times before use. 
2. Use a standard in order to obtain a standard curve. 
3. Pipet each standard and unknown sample solution into separate clean test 
tubes or microplate wells (the 1 ml assay may be performed in disposable 
cuvettes). Add the 1x dye reagent to each tube (or cuvette) and vortex (or 
invert). 
 
Assay: 1,020 µl 
Volume of standard and sample: 20 µl 
Volume of 1x dye reagent: 1 ml 
 
4. Incubate at room temperature for at least 5 minutes. Samples should not be 
incubated longer than 1 hour at room temperature. 
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5. Set the spectrophotometer to 595 nm. Zero the instrument with the blank 
sample (not required for microplate readers). Measure the absorbance of the 
standards and unknown samples. 
6. Using the calibration curve, determine the concentration of the protein. 
 
Spectrophotometry is the experimental technique that analyzes and quantifies the 
absorbance (light absorption). This technique requires a spectrophotometer, which can 
quantify intensity as a function of the light wavelength. The spectrophotometers can be 
classified as single beam or double beam. In this experimental work, a double beam 
spectrophotometer was used, that measures the absolute light intensity. Usually they are 
equipped with a monochromator that analyses the spectrum. Basically, the 
spectrophotometer quantifies the fraction of light that passes through a given solution. 
The intensity of the remaining light is determined using a photodiode, and the 
transmittance of the wavelength is calculated automatically. 
 
Standard curve 
 
Use the standard below to calculate the protein concentration. 
 
y = 0.05831 x + 0.1154 
R2 = 0.9315  
 
y – OD (595 nm) 
x – Protein concentration (mg/ml)  
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Figure A.2.2.1.: Bradford protein assay. 
 
Focusing on the first part of the graph, we can determine another equation suitable for 
samples with lower concentration values: 
 
 
Figure A.2.2.2.: Bradford protein assay. 
 
A.2.3. SDS-PAGE analysis of proteins 
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Table A.4: Reagents required for the casting of mini-SDS-PAGE (sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis) gels. 
Components Stacking gel 
4 % 
Separating gel 
12 % 15 % 
dH2O 3.63 ml 3.34 ml 2.34 ml 
1.5 M Tris-HCL pH 
8.8 
- 2.5 ml 2.5 ml 
1 M Tris-HCL pH 6.8 625 µl - - 
10 % (w/v) SDS 50 µl 100 µl 100 µl 
Acrylamide (29 %) 
Bis (1 %) 
667 µl 4 ml 5 ml 
Ammonium 
persulfate 10 % 
25 µl 50 µl 50 µl 
TEMED 5 µl 10 µl 10 µl 
Total 5 ml 10 ml 10 ml 
 
- Assemble the glass plates on the gel casting stand and fill with water to ensure 
that they are sealed. 
- Mix the components of separating gel, adding the TEMED (N, N, N’,N’ – 
Tetramethylethylene-diamine, for electrophoresis, approx. 99 % C6H16N2) last. 
Mix well and immediately fill the glass plates, leaving a 1.5 cm gap at the top 
(for the stacking gel). 
- Immediately add 1 ml of isopropanol on top of the gel to prevent oxygen from 
inhibiting the polymerization. Wait 20 minutes for solidification. 
- Pour off the isopropanol and rinse with dH2O to remove any residual 
isopropanol. Mix the components for the 4 % staking gel and pour on top of the 
separating gel. Insert the well-comb and wait 20 minutes for solidification. 
- Preheat a water bath to 100 ºC. 
- Prepare the SDS-PAGE loading buffer by diluting β-mercaptoethanol 20 X 
(1:20) with the SDS-blue buffer. 
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- For a 4 ml culture with an approximate OD600 of 0.8, add 600 µl of SLB to the 
cold, centrifuged pellet. Suspend pellet in the SLB by vortexing. 
- Immediately heat the sample to 100 ºC for 2 minutes. 
- Allow the samples to cool down for at least one minute before loading the gel. 
- Assemble the solidified gels in the buffer chamber. Fill the chamber with 
running buffer. 
- Load 10 µl of each protein sample into the wells. Run the gel at a constant 
voltage of 165 V for about 1 hour, or until the dye reaches the bottom of the gel. 
- Cut off the stacking gel and discard it. 
- Stain the separating gel with a staining solution containing 45 % (w/v) dH2O, 45 
% (w/v) methanol, 10 % (v/v) acetic acid and 0.25 % (w/v) Coomassie Brilliant 
Blue R250. Stain for 1 hour with gentle shaking. If shaking is not possible, an 
overnight incubation will be sufficient. 
- Pour the stain back into its container (it can be re-used several times) and rinse 
the tray with water. To remove the extra stain on the gel, use a destain solution 
(same as the staining solution, but without the Coomassie Blue). Protein bands 
will be visible immediately on a light table. 
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Table A.5: Marker molecular weights (BIO-RAD Laboratories (Hercules, CA)). 
Protein Calibrated MW 
(daltons) 
Calibrated MW 
(daltons) 
Calibrated MW 
(daltons) 
Myosin 202,816 196,496 196,373 
β-galactosidase 115,556 109,828 112,519 
Bovine serum 
albumin 
98,223 59,375 70,546 
Ovalbumin 51,366 41,485 42,798 
Carbonic anhydrase 37,240 28,224 31,635 
Soybean trypsin 
inhibitor 
29,003 20,261  
Lypozyme 19,748 15,013  
Aprotinin 6,658 6,494  
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A.2.4. Freeze dryer protocol 
 
1. Make sure that there is ethanol in the freezing well vacuum trap. 
2. Turn on the vacuum trap and wait till red lights turns to green, indicating that 
ethanol in freezing well reached the appropriate temperature (~ -110 ºC) (approx 
1 h). 
3. Turn on the vacuum pump. (Make sure there’s oil in the pump) 
4. Turn on the freeze dryer wait till the pressure drops (approx. 1 h). 
a. Top light in the gauge reads higher pressures 
b. Bottom light reads low pressures 
c. Drain valve is completely closed 
d. Vent valve is completely closed 
5. Make sure that there is no leak in the freeze dryer. Presently only one vent is 
used to dry the samples, stoppers close all other vents. 
6. Make sure there is ice in the small Styrofoam box and place this box in the big 
Styrofoam box. 
7. Place the filter paper under the freeze dryer cap (freeze dryer cap is connected to 
freeze dryer by a long tube). 
8. Place the sample in the 20 ml freeze dryer vials (either in centrifuge tubes or 
other long tubes).  
9. Place the 20 ml freeze dryer vial in the small Styrofoam box containing ice 
(make sure vial is completely immersed in ice). 
10. Close the vial with black cap containing filter paper. 
11. Open the vent valve on the freeze dryer. 
12. Wait until the sample is completely freeze dried. 
13. After complete drying, turn off all the equipment. 
14. Open the drain valve on the freeze dryer, slowly to release the pressure. 
15. Take the sample vial and store. 
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Note.  Sometimes if the sample volume is large, sample will melt after few hours, if this 
is the case, use dry ice instead of ice in the Styrofoam box (This can happen due to 
inefficiency of the whole system). 
 
FREEZE DRYING 
 
FREEZE DRYING WITH RUBBER VALVES 
 
1. Start the vacuum pump. 
The start switch is placed on top of the pump. 
2. Open the gas ballast valve on the pump. 
3. Check the oil level in the vacuum pump. 
The oil level glass must be ½ to 1/1 full. 
4. Check the oil level in the oil mist filter. 
Drain the oil if the oil level glass is more than ½ full. 
5. Check that the ice condenser is free from ice and water. 
6. Check that the rubber valves are all closed, and that the grey cone is inserted in 
the top of the unit. 
7. Check that the drain valve is closed. 
8. Start the freeze dryer. 
WAIT. 
The cooling unit and vacuum pump should be allowed to run for 30 minutes 
before the freeze drying is started. 
9. Open the vacuum valve. 
Wait for the pressure to drop below 0.5 mbar and for the temperature to drop 
below -30 ºC. 
10. Connect the flask with the frozen material to the rubber valve, and slowly open 
the valve, turning your face away from the flask. 
The freeze drying (sublimation) is now running. 
Before connecting the next flask, wait for the pressure to drop below 0.5 mbar. 
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STOPPING THE FREEZE DRYING 
 
11. Turn the rubber valve handle 180º to pressure equalize the pressure in the flask, 
and remove the flask. 
12. Close the vacuum valve after removal of the last flask. 
13. Switch off the freeze dryer. 
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A.2.5. Determination of the SWNT calibration curve 
 
Principle 
 
The assay aims to determine a generic calibration curve that can be used to determine 
the concentration of a specific sample where the concentration is not known. Due to the 
fact that there is not a relevant peak of absorption at 800 nm, that wavelength was 
chosen as standard to determine the absorbance of any sample. 
 
Protocol 
 
A suspension of SWNTs was prepared using the standard procedures already presented 
in the experimental section of this dissertation. The sample was then diluted using 4 
different dilution factors. An UV-VIS-NIR spectrum was obtained for each sample. The 
absorbance values at 800 nm were then recorded on a table. Those values were then 
matched with the respective sample concentrations, and a curve was plotted based on 
the data. A linear regression was applied and an equation was generated. 
 
Standard 
 
Use the standard below to determine the SWNT concentration. 
 
y = 0.0176 x + 0.0218 
R2 = 0.9959  
 
y – OD (800 nm) 
x – SWNT concentration (mg/L)  
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Figure A.2.5.1.: SWNT calibration curve. 
136 
 
 APPENDIX B 
 
Annexin V protein structure 
Theoretical pI/Mw (average) for the user-entered sequence: 
 
        10         20         30         40         50         60  
MAQVLRGTVT DFPGFDERAD AETLRKAMKG LGTDEESILT LLTSRSNAQR QEISAAFKTL  
 
        70         80         90        100        110        120  
FGRDLLDDLK SELTGKFEKL IVALMKPSRL YDAYELKHAL KGAGTNEKVL TEIIASRTPE  
 
       130        140        150        160        170        180  
ELRAIKQVYE EEYGSSLEDD VVGDTSGYYQ RMLVVLLQAN RDPDAGIDEA QVEQDAQALF  
 
       190        200        210        220        230        240  
QAGELKWGTD EEKFITIFGT RSVSHLRKVF DKYMTISGFQ IEETIDRETS GNLEQLLLAV  
 
       250        260        270        280        290        300  
VKSIRSIPAY LAETLYYAMK GAGTDDHTLI RVMVSRSEID LFNIRKEFRK NFATSLYSMI  
 
       310        320  
KGDTSGDYKK ALLLLCGEDD  
Theoretical pI/Mw: 4.94 / 35936.77 
[144] 
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APPENDIX C 
 
EDC (Pierce Catalog) 
 
Number Description 
22980 EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride), 5 g 
22981 EDC, 25 g 
77149 EDC, 10 mg 
 Molecular Weight: 191.7 
CAS # 25952-53-8   
 Storage: Upon receipt store Product No. 22980 and 22981 desiccated at        
- 20 °C. Store Product No. 77149 at 4 °C. EDC is shipped at ambient 
temperature. 
 
 
Introduction 
 
EDC is a carboxyl and amine-reactive zero-length crosslinker. EDC reacts with a 
carboxyl group first and forms an aminereactive O-acylisourea intermediate that quickly 
reacts with an amino group to form an amide bond and release of an isourea by-product 
(see the Additional Information Section). The intermediate is unstable in aqueous 
solutions, and therefore, two-step conjugation procedures require N-
hydroxysuccinimide for stabilization [145, 146]. Failure to react with an amine will 
result in hydrolysis of the intermediate, regeneration of the carboxyl and release of an 
N-substituted urea. A side reaction is the formation of an N-acylurea, which is usually 
restricted to carboxyls located in hydrophobic regions of proteins [145, 147]. 
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APPENDIX D 
 
Procedure for Two-step Coupling of Proteins Using EDC and NHS or Sulfo-NHS 
 
The following protocol is adapted from a procedure described by Grabarek and Gergely 
[145] and allows sequential coupling of two proteins without affecting the second 
protein’s carboxyls by exposing them to EDC. This procedure requires quenching the 
first reaction with a thiol-containing compound. 
 
Materials Required 
 
• Activation Buffer: 0.1 M MES, 0.5 M NaCl, pH 6.0 
• Protein # 1: Prepared in Activation Buffer at 1 mg/ml 
• Protein # 2 
• NHS or Sulfo-NHS (Product No. 24500 and 24510, respectively) 
• 2-Mercaptoethanol (Product No. 35600) 
• (Optional) Zeba™ Desalt Spin Column (Product No. 89891) or other gel filtration 
column 
• Hydroxylamine•HCl (Product No. 26103) 
 
Procedure 
1. Equilibrate EDC and NHS to room temperature before opening bottles. 
2. Add 0.4 mg EDC (~2 mM) and 0.6 mg of NHS or 1.1 mg of sulfo-NHS (~5 mM) to 1 
ml of protein #1 solution and react for 15 minutes at room temperature. 
3. Add 1.4 μl of 2-mercaptoethanol (final concentration of 20 mM) to quench the EDC. 
4. Optional: Separate the protein from excess reducing agent and inactivated crosslinker 
using a desalting column. Equilibrate the column with Activation Buffer. 
5. Add protein #2 to the activated protein at an equal molar ratio with protein #1. Allow 
the proteins to react for 2 hours at room temperature. 
6. To quench the reaction, add hydroxylamine to a final concentration of 10 mM. This 
method hydrolyzes nonreacted NHS present on protein #1 and results in regeneration of 
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the original carboxyls. Other quenching methods involve adding 20-50 mM Tris, lysine, 
glycine or ethanolamine; however, these primary amine-containing compounds modify 
carboxyls on protein #1. 
7. Remove excess quenching reagent using a desalting column. 
 
 
 
 
 
Figure D.1: EDC reacts with carboxylic acids to create an active-ester intermediate. In 
the presence of an amine nucleophile, an amide bond is formed with release of an 
isourea by product. 
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APPENDIX E 
 
o-Phenylenediamine 
 
Product Number: P 5412 
Storage Temperature: 2-8 ºC 
 
Product Description 
Molecular Formula: C6H8N2 
Molecular Weight: 108.1 
CAS Number: 95-54-5 
 
Synonyms: 1,2-Benzenediamine, 1 OPD 
 
o-Phenylenediamine (free base) is a chromogenic substrate suitable for use in ELISA 
procedures which utilize horseradish peroxidase conjugates.2,3 This substrate produces a 
soluble end product that is orange-brown in color and can be read 
spectrophotometrically at 450 nm. The OPD reaction may be stopped with 3 N HCl or 3 
M H2SO4, and read at 492 nm. 
 
This product is supplied as 50 or 100 tablets per box, individually foil wrapped for ease 
of use, storage, and safety. Each tablet weights approximately 45 mg (range 40-50 mg) 
and contains 20 mg of substrate. One tablet, dissolved in 10 ml of water, gives a 
solution with a pH of 9.0 (range 8.5-9.5). The background absorbance of this solution 
cannot be more than 0.04. 
 
Precautions and Disclaimer 
For Laboratory Use Only. Not for drug, household or other uses. 
 
Storage/Stability 
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Store tablets at 2-8 ºC. Protect from heat, light and moisture. Allow to reach room 
temperature before use. Solutions should be freshly prepared. 
 
Procedure 
Dissolve one tablet in 0.05 M phosphate-citrate buffer, pH 5.0, to the desired 
concentration (typically an OPD concentration of 0.4 mg/ml is used). Add 40 µl of fresh 
30 % hydrogen peroxide (Product No. H 1009) per 100 ml of substrate buffer solution, 
immediately prior to use. 
 
To prepare 0.05 M phosphate-citrate buffer, pH 5.0: Add 25.7 ml of 0.2 M dibasic 
sodium phosphate, (Product No. S 0876), 24.3 ml of 0.l M citric acid (Product No. C 
7129) and 50 ml of water. Adjust the pH to 5.0, if necessary. Alternatively, use 
phosphate-citrate buffer capsules containing sodium perborate (Product No. P 4922). If 
these capsules are used, it is not necessary to add H2O2 to the substrate solution since 
sodium perborate is a substitute for hydrogen peroxide. 
 
Troubleshooting 
If the background is too high: 
1. Use a blocking step prior to the application of the primary antibody. Normal 
serum (5 % v/v) from the same species as the host of the second antibody 
generally produces the best results. 
2. Additional blocking agents for an ELISA are: 
a. 0.05 % TWEEN® 20 in 50 mM TBS, pH 8.0. 
b. 1 % BSA containing 0.05 % TWEEN 20 in 50 mM TBS, pH 8.0. 
c. 3 % nonfat-dried milk in 0.01 M TBS (Product No. P 2194). Do not use milk 
as a blocking agent when using avidin-biotin systems. 
3. Use 0.05 % TWEEN 20 in all washing and antibody diluents buffers. 
4. Run control wells without the primary antibody to check for non-specific 
reactivity of the secondary antibody. 
5. Titer the primary antibody and the conjugate to optimize working dilutions. 
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If no color develops or the color is too faint: 
1. Adjust the concentration of the primary antibody. 
2. Adjust the concentration of the secondary antibody. 
3. Determine if the enzyme conjugate is active by mixing a small sample of 
substrate and conjugate together in a test tube. 
4. Increase the reaction time or temperature. 
5. Adjust the concentration of the coating antigen. 
6. Consider using an amplifying system such as avidin-biotin. 
 
References 
1. The Merck Index, 11th ed., Entry# 7355. 
2. Wolters, G., et al., Solid-phase enzyme-immunoassay for detection of hepatitis 
B surface antigen. J. Clin. Path., 29(10), 873-879 (1976). 
3. Bovaird, J. H., et al., Optimizing the o-phenylenediamine assay for horseradish 
peroxidase: effects of phosphate and pH, substrate and enzyme concentrations, 
and stopping reagents. Clin. Chem., 28(12), 2423-2426 (1982). 
 
TWEEN is a registered trademark of Uniqema, a business unit of ICI America, Inc. 
CMH/RXR 3/03
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APPENDIX F 
 
General Information about Human Endothelial Cells [148]  
 
ATCC Information about the Human Endothelial Cells 
 
Cell Biology ATCC® Number: CRL-2472™ 
 
Designations:  HAAE-1 [Part of the Wistar Special Collection]  
Depositors:   EM Levine, Wistar Institute  
Biosafety Level:  1  
Shipped:  frozen  
Medium & Serum:  See Propagation  
Growth Properties: Adherent 
Organism: Homo sapiens (human)  
Morphology: 
 
endothelial 
 
Source: 
Organ: aorta, abdominal  
Disease: normal  
Cell Type: endothelial 
Permits/Forms: 
 
In addition to the MTA mentioned above, other ATCC 
and/or regulatory permits may be required for the transfer of 
this ATCC material. Anyone purchasing ATCC material is 
ultimately responsible for obtaining the permits. Please click 
here for information regarding the specific requirements for 
shipment to your location.  
Restrictions: Distribution of this cell line is governed by the Wistar 
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Special Collection Material Transfer Agreement.  
DNA Profile (STR): 
 
Amelogenin: X,Y  
CSF1PO: 11  
D13S317: 8  
D16S539: 13  
D5S818: 12,13  
D7S820: 10  
THO1: 8,9.3  
TPOX: 9,11  
vWA: 16,17 
  
Age:  20 years  
Gender:  male  
  
Comments: 
A frozen ampule at population doubling 16 was received at 
the ATCC in June, 1999. Cells have the potential to reach 
approximately 46 population doublings before the onset of 
senescence. Check product sheet to see the PDL of the 
current distribution stock. 
Propagation:  
 
ATCC complete growth medium: Ham's F12K medium 
with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate and supplemented with 0.1 mg/ml heparin and 
0.03 mg/ml endothelial cell growth supplement (ECGS), 
90 %; fetal bovine serum, 10 % 
Temperature: 37.0°C  
Growth Conditions: Culture vessels used to propagate 
this line must be precoated with 0.1 % pig gelatin. To 
prepare, flood vessels with gelatin solution, and leave on 
for at least 5 to 10 minutes. Suction off excess gelatin prior 
to use. Vessels may be used immediately. 
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Subculturing:  
 
Protocol: Remove medium, and rinse with 0.25 % trypsin 
- 0.53 mM EDTA solution. Remove the solution and add 
an additional 1 to 2 ml of trypsin-EDTA solution. Allow 
the flask to sit at room temperature (or at 37 ºC) until the 
cells detach. Add fresh culture medium, aspirate and 
dispense into new culture flasks.  
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 
is recommended  
Medium Renewal: Every 2 to 3 days 
Preservation:  
Freeze medium: culture medium 95 %; DMSO, 5 %  
Storage temperature: liquid nitrogen vapor phase   
Related Products: recommended serum:ATCC 30-2020 
References: 
46534: Levine EM, et al. Process and medium for cloning 
and long-term serial cultivation of human endothelial cells. 
US Patent 4,994,387 dated Feb 19 1991 
46535: Levine EM, et al. Process and medium for cloning 
and long-term serial cultivation of adult human endothelial 
cells. US Patent 5,132,223 dated Jul 21 1992 
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APPENDIX G 
 
Kaighn’s Modification of Ham’s F-12 Medium Formulation [149]  
 
ATCC 
 
F-12 K Medium 
 
Kaighn’s Modification of Ham’s F-12 Medium 
 
Formulation 
 
Catalog No. 30-2004 
 
 
Inorganic Salts  (g/liter) Vitamins (g/liter) 
CaCl2·2H2O 0.13524 D-Biotin 0.0000733 
CuSO4·5H2O 0.0000025 Choline Chloride 0.01396 
FeSO4·7H2O 0.000834 Folic Acid 0.00132 
MgCl2·6H2O 0.10572 Hypoxanthine 0.00408 
MgSO4 (anhydrous) 0.19264 myo-Inositol 0.01802 
KCl 0.28329 Nicotinamide 0.0000366 
KH2PO4 (anhydrous) 0.05852 D-Pantothenic Acid 
(hemicalcium) 
0.000477 
NaHCO3 1.50000 Putrescine·2HCl 0.000322 
Na2HPO4 
(anhydrous) 
0.11502 Pyridoxine·HCl 0.0000617 
NaCl 7.59720 Riboflavin 0.0000376 
ZnSO4·7H2O 0.000144 Thiamine·HCl 0.000337 
  Thymidine 0.000727 
  Vitamin B-12 0.001355 
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Amino Acids  (g/liter) Other  (g/liter) 
L-Arginine (free 
base) 
0.42140 D-Glucose 1.26000 
L-Alanine 0.01782 Phenol Red. Sodium 
Salt 
0.00332 
L-Asparagine·H2O 0.03020 Sodium Pyruvate 0.22000 
L-Aspartic Acid 0.02662 Lipoic Acid 0.00021 
L-Cysteine·HCl·H2O 0.07024   
L-Isoleucine 0.02942   
L-Leucine 0.29220   
L-Lysine·HCl 0.01501   
L-Methionine 0.04192   
L-Phenylalanine    
L-Proline    
L-Serine    
L-Threonine    
L-Tryptophan    
L-Tyrosine (free 
base) 
L-Valine 
   
    
 
148 
 
F-12 K Medium, Modified 
Kaighn’s Modification of Ham’s F-12 Medium 
CATALOG NO. 30-2004, 500 Ml 
 
Storage 
Store medium at 2 to 8 ºC in the yellow plastic bag when not in use. The yellow bag 
minimizes the effect of light on some of the components in the medium. 
 
Quality Control Testing 
Sterility tests are performed on each lot of medium using current USP methods. ATCC 
also checks each lot of medium for its ability to support the growth of several different 
cell lines using both sequential subcultures and plating efficiencies. Additional test 
results are listed below in the Specification Certificate. 
 
Formulation 
Contains 2 mM L-glutamine and 1500 mg/L sodium bicarbonate. 
NOTE: This reduced level of sodium bicarbonate (NaHCO3, 1.5 g/L) is intended for use 
in 5 % CO2 in air. Additional sodium bicarbonate may be required for use in incubators 
containing higher percentages of CO2. 
 
Terms and Conditions 
Please refer to the Material Transfer Agreement and Packing Slip enclosed with the 
product. 
 
SPECIFICATION CERTIFICATE 
 
Test/Method Specification Results 
pH 7.0 to 7.4 See lot specific data 
Osmolality 275 to 357 mOsm/kg See lot specific data 
Sterility Testing Pass See lot specific data 
Endotoxin 0.25 EU/mL See lot specific data 
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Mycoplasma Not Detected See lot specific data 
Growth Promotion Pass See lot specific data 
 
Lot number: 3000608 
F-12K Medium, Modified 
Kaighn’s Modification of Ham’s F-12 Medium 
 
ATCC Catalog No.: 30-2004, 500 mL 
Lot No.: 3000608 Expiration Date: FEB/2009 
 
pH: 7.2 
Osmolality: 336 mOsm/kg 
Sterility Testing: Pass 
Endotoxin: < 0.0050 EU/Ml 
Mycoplasma: Negative 
Growth Promotion: Pass 
 
Trypsin-EDTA 
0.25 % Trypsin/0.53 mM EDTA Solution 
In Hank’s BSS without Calcium or Magnesium 
CATALOG NO. 30-2101, 100 Ml 
 
Storage 
Store Trypsin-EDTA solution frozen, between -5 and -20 ºC. Avoid repeated freeze-
thaws by dispensing and storing in aliquots. 
 
Application 
For the dissociation of cell monolayers. NOTE: Each cell line responds to ATCC® 
Trypsin-EDTA solution in a unique manner. For optimum results, observe the cells 
during the dissociation process to avoid over-trypsinization. For more information, 
please refer to the General Protocol for Using ATCC® Trypsin-EDTA Solution. For cell 
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line-specific information, please refer to the product sheet supplied with the cell line, or 
contact ATCC® Technical Service. ATCC ® Trypsin-EDTA solution is suitable for most 
but not all adherent cell lines. 
 
SPECIFICATION CERTIFICATE 
Test/Method Specification Results 
pH 7.0 to 7.4 See lot specific data 
Osmolality 283 to 313 mOsm/kg See lot specific data 
Sterility Testing Pass See lot specific data 
Cell Culture Tests – MRC-
5 (CCL-171) 
Pass See lot specific data 
Cell Culture Tests – Vero 
(CCL-81) 
Pass  
Source Pass (Porcine) See lot specific data 
Porcine Parvovirus (PPV) Not Detected See lot specific data 
Mycoplasma Not Detected See lot specific data 
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APPENDIX H 
 
General Protocol for Using ATCC® Trypsin-EDTA Solution [149] 
 
Catalog No. 30-2101 
Storage 
Store ATCC® Trypsin-EDTA solution frozen between -5 and -20 ºC. Avoid repeated 
freeze-thaws by dispensing and storing in aliquots. 
 
General Procedures for Adherent Cell Lines 
NOTE: Each cell line responds to ATCC® Trypsin-EDTA in a unique manner. For 
optimum results, continually observe the cells by microscopy during the dissociation 
process to prevent damage by the Trypsin-EDTA solution. For cell-line-specific 
information, please refer to the product sheet supplied with the cell line, or contact 
ATCC® Technical Service. 
 
The amounts used in this procedure are for a 75-cm2 flask. Adjust volumes as 
appropriate for different sized vessels. 
 
1. Bring ATCC® Trypsin-EDTA solution to the appropriate temperature (see cell 
line product sheet). This may be 4 ºC, room temperature, or 37 ºC depending 
upon the cell type. You may also need to use a balanced salt solution [e.g., 
ATCC® Dulbecco’s Phosphate Buffered Saline (PBS) without Ca or Mg, 
Catalog number 30-2200] to rinse the cells. If so, bring this to the same 
temperature. Finally, bring fresh, complete cell culture medium to the 
appropriate temperature for cell growth (e.g., 37 ºC). 
2. Remove and discard the cell culture medium from the flask. 
3. Depending upon the cell line, rinse the cell monolayer with either 5 mL of 
ATCC® Trypsin-EDTA solution or ATCC® Dulbelcoo’s PBS (for more trypsin-
sensitive cells) and remove. 
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4. Add 2 to 3 mL of ATCC® Trypsin-EDTA solution and incubate at the 
appropriate temperature (4 ºC, room temperature, or 37 ºC). Continually check 
the progress of cell dissociation by microscopy. To avoid clumping, do not 
agitate the cells by hitting or shaking the flask while waiting for them to detach.  
5. Once the cells appear to be detached (5 to 15 minutes for most cell lines, they 
will appear rounded under the microscope), add 6 to 8 mL of complete growth 
medium to the cell suspension and with a pipette wash any remaining cells from 
the bottom of the flask. Check the cells with the microscope to be sure that most 
(> 95%) exist as single cells. If cell clusters are apparent, continue to disperse 
the cells with gentle pipetting (see Troubleshooting, below). 
6. Add 12 to 15 mL of fresh cell culture medium to a new flask and equilibrate this 
medium to the appropriate pH and temperature. Collect the cell suspension, 
count and/or divide it, and dispense the cells into the newly prepared flask. 
Refer to the cell line product sheet for recommended subcultivation ratios. 
7. For serum free or low serum medium, remove the ATCC® Trypsin-EDTA 
solution by gentle centrifugation (5 minutes at 125 x g) and resuspend the cells 
in fresh medium. 
 
Troubleshooting 
Cells are difficult to remove: 
• The dissociation agent is too weak. Try incubating at higher temperatures. 
• Inhibitors in the medium (e.g., serum) are inactivating the trypsin. Rinse the cell 
monolayer more thoroughly before incubating with ATCC® Trypsin-EDTA 
solution. 
• Cells have been at confluent density for a too long and the cell-to-cell junctions 
are so tight that they are preventing the enzyme from reaching the substrate-cell 
interface. Subculture cells before they are 100 % confluent. 
Cells clump after dissociation: 
• DNA has been released from lysed cells, because the dissociation procedure was 
too harsh. Add a drop of sterile DNAse (1 mg/ml in water) to the cell 
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suspension. In the future, treat the cells more gently during pipetting, shorten the 
incubation period, and/or decrease the incubation temperature. 
• Cells are reaggregating before subculturing. Hold the cell suspension on ice if 
there will be a delay between removing cells from the flask and dispersing them 
into them fresh cell culture medium. 
Cells have difficulty reattaching: 
• The dissociation enzymes may have stripped necessary attachment proteins from 
the cell surface. Treat the cells more gently, use less ATCC® Trypsin-EDTA 
solution, shorten the incubation time, and/or lower the incubation temperature. 
• Not enough serum or attachment factors are in the medium (common with 
serum-free medium). Add attachment factors or use protein-coated plates 
(collagen, polylysin, gelatin, etc.). 
• ATCC® Trypsin-EDTA solution was not inactivated by the cell culture medium 
(e.g., the serum). Add specific enzyme inhibitors or remove the ATCC® 
Trypsin-EDTA solution by gentle centrifugation (5 minutes at 125 x g) followed 
by a medium change. 
 
Lot number: 3000620 
Trypsin-EDTA 
0.25 % Trypsin/0.53 mM EDTA Solution 
in Hank’s BSS without Calcium or Magnesium 
 
ATCC Catalog No.: 31-2101, 100 mL 
Lot No.: 300620 Expiration Date: 05/09 
 
pH: 7.0 
Osmolality: 288 mOsm/kg 
Sterility Testing: Pass 
Cell Culture Tests – MRC-5 (CCL-171): Pass 
Cell Culture Tests – Vero (CCL-81): Pass 
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Source: Pass (Porcine) 
Porcine Parvovirus (PPV): Negative 
Mycoplasma: Negative 
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APPENDIX I 
 
General Protocol for Using Accutase Solution [150] 
 
ACCUTASE 
 
CATALOG #: AT104-500 LOT: 8P1215A EXP: 3/2010 
DESCRIPTION: A cell detachment solution of proteolytic and collagenolytic enzymes. 
Useful for the routine detachment of cells from standard tissue culture plasticware and 
adhesion coated plasticware. ACCUTASE does not contain mammalian or bacterial 
derived products. 
FORMAT: 500 ml, ready to use, frozen sterile liquid. 
QUALITY CONTROL: 1. Sterility testing by USP membrane filtration method. 
2. Enzymatic activity tested with synthetic chromagenic           
tetrapeptides. 
3. Cell detachment from plastic tissue culture dishes. 
FORMULATION: 1X ACCUTASE enzymes in Dulbecco’s PBS (0.2 g/L KCL, 0.2 g/L 
KH2PO4, 8 g/L NaCl, and 1.15 g/L Na2HPO4) containing 0.5 mM EDTA·4Na and 3 
mg/L Phenol Red. 
STABILITY: Stable when stored at -20 ºC. Refer to lot expiration date. Recommended 
storage upon receipt is -20 ºC. After thawing, ACCUTASE may be stored for up to 2 
months at 4 ºC. DO NOT STORE AT ROOM TEMP. 
PROCEDURE: 1. Thaw ACCUTASE in the refrigerator overnight, in a vessel 
of cool water or at room temperature. Not at 37 ºC. 
 2. Wash plate, flask or beads with sterile PBS. 
 3. Add ACCUTASE to culture dish or flask using aseptic 
procedures at 10 ml per 75-cm2 surface area. 
 4. Incubate at room temperature and allow cells to detach 5-10 
minutes. 
 5. Count cells and passage as usual; no additional washes or 
enzyme inhibitors are required. 
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APPENDIX J 
 
General Protocol for the Hemacytometer [151] 
 
Metallized Hemacytometer 
 
Reichert Bright-Line 
 
The Bright-Line Hemacytometer is molded from a single piece of thermal and shock-
resistant glass. An H-shaped moat forms two counting areas, or plateaus. A "V" slash at 
the loading side of each plateau facilitates charing and reduces the possibility of 
overflow into the moat. Each plateau features enhanced Neubauer rulings. The ruled 
surface is 0.1 mm below the cover glass, limiting the volume of blood or fluid over a 
square mm at 0.1 cu.mm and over each of 400 squares (within the central square mm) to 
0.00025 cu. mm. Contact of the flat, polished cover glass surfaces with cover glass 
supports produces an exact volume of fluid over the counting area. The difference in 
surface tension characteristics between the metallic surface on the chamber and the 
polished cover glass assures smooth capillarity for precise loading and more even cell 
distribution. 
 
 
Figure J.1: Photograph of 1490 
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Figure J.2: Photograph of 1475  
Directions for Use 
Bright-Line / Dark-Line Counting Chambers 
Catalog Numbers: 3100, 3110, 3200, 3500, 1490, 1492, 1475, & 1483  
 
Usage: Cell Counts 
Cell Depth: 0.100 mm +/- 2% (1/10 mm) 
Volume: 0.1 Microliter 
Ruling Pattern: Improved Neubauer, 1/400 Square mm 
Rulings cover 9 square millimeters. Boundary lines of the Neubauer ruling are the 
center lines of the groups of three. (These are indicated in the illustration below.) The 
central square millimeter is ruled into 25 groups of 16 small squares, each group 
separated by triple lines, the middle one of which is the boundary. The ruled surface is 
0.10 mm below the cover glass, so that the volume over each of the 16 small squares is 
.00025 cubic mm. 
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Figure J.3: Neubauer Ruling. 
  
The number of cells per cubic millimeter =  
         Number of cells counted per square millimeter X dilution (if used) X 10 
The number of cells per milliliter =  
        Number of cells counted per square millimeter X dilution (if used) X 10,000 
One (1) Milliliter = 1000 cubic millimeters (cu mm) 
One (1) Microliter (ul) = One (1) cubic millimeter (cu mm) 
To clean the counting chamber: After completing the count, remove the cover glass and 
clean the counting chamber with water or a mild cleaning solution (10 % solution of 
bleach). Dry the counting chamber with a soft cloth or wipe, or rinse with acetone. 
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APPENDIX K 
 
General Protocol for Using the Alamar Blue Assay [152] 
 
IN VITRO TOXICOLOGY ASSAY KIT 
Resazurin Based 
 
Stock No. TOX-8 
 
Store at 2-8 ºC 
 
This kit is designed for fluorometrically or spectrophotometrically determining cell 
number as a function of metabolic activity using the dye resazurin. 
 
IT IS RECOMMENDED THAT THE ENTIRE PROTOCOL BE REVIEWED 
BEFORE STARTING THE ASSAY. 
 
Product Description 
Traditionally, the toxic effects of unknown compounds have been measured in vitro by 
counting viable cells after staining with a vital dye. Alternative methods include the 
measurement of DNA synthesis by radioisotope incorporation, cell counting by 
automated counters and other methods which rely on dyes and cellular activity. The 
resazurin system measures the metabolic activity of living cells. The resazurin method 
is simple, accurate and reproducible. The key component is the oxidoreduction indicator 
dye resazurin. Solutions of resazurin, prepared in balanced salt solutions without phenol 
red, are dark blue in color. Bioreduction of the dye by viable cells reduces the amount 
of its oxidized form [blue] and concomitantly increases the amount of its fluorescent 
intermediate [red],indicating the degree of cytotoxicity caused by the test material. The 
amount of dye conversion in solution is measured fluorometrically or 
spectrophotometrically. 
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REAGENT 
For Research Use Only. 
Not for Use in Diagnostic Procedures. 
 
 
Kit Components 
 
Catalog No. Item  Quantity 
R-6892 Resazurin Solution 25 ml 
 
Procedure 
The resazurin method of monitoring in vitrocytotoxicity is well suited for use with 
multiwell plates. For best results, use cells in the log phase of growth and a final cell 
density less than 106 cells/cm2. Each test should include a blank containing complete 
medium without cells. 
 
NOTE: Bacteria, mycoplasma and other microbial contaminants may also reduce the 
resazurin dye. Cultures containing microorganisms should not be assayed using this 
method. 
 
1. Remove cultures from incubator into laminar flow hood or other sterile work area. 
2. Add resazurin dye solution in an amount equal to 10 % of the culture medium 
volume. 
3. Return cultures to incubator for 2-4 hours depending on cell type and maximum cell 
density. (An incubation period of 2 hours is generally adequate but may be lengthened 
for low cell densities or cells with lower metabolic activity.) Incubation times should be 
consistent when making comparisons. 
4. Gentle mixing in a gyratory shaker will enhance distribution of the dye. 
5. Samples can be measured spectrophotometrically by monitoring the decrease in 
absorbance at a wavelength of 600 nm. Measure the absorbance of multiwall plates at a 
reference wavelength of 690 nm and subtract from the 600 nm measurement. 
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Alternatively, samples can be measured fluorometrically by monitoring the increase in 
fluorescence at a wavelength of 590 nm using a excitation wavelength of 560 nm. 
NOTE: Fluorometric detection is much more sensitive than spectrophotometric 
detection and the number of cells used in the assay should be reduced proportionally. 
6. Tests performed in multiwell plates can be read using an appropriate type of plate 
reader or the contents of individual wells may be transferred to appropriate size cuvettes 
for fluorometric or spectrophotometric measurement. 
 
Possible Sources of Error 
1. Microbial contamination will contribute to the reduction of the resazurin dye yielding 
erroneous results. 
2. Uneven evaporation of culture fluid in wells of multiwell plates may cause erroneous 
results. 
3. Medium and salt solutions with phenol red can be used but will contribute to higher 
background absorbance and can decrease sensitivity. 
 
References 
1. Dutka, B.J., N. Nyholm and J Petersen. [1983] Comparison of several 
microbiological toxicity screening tests. Water Research 17:1363-1367. 
2. King, E.F. [1984] A comparative study of methods for assessing the toxicity to 
bacteria of single chemicals and mixtures. In: Toxicity Screening Procedures Using 
Bacterial Systems, D. Liu and B.J. Dutka eds., Decker, New York. pp. 175-194. 
3. Liu, D. [1981] A rapid biochemical test for measuring chemical toxicity. Bull. 
Environmental Contamination Toxicology 26:145-149. 
4. Strotmann, U.J., B. Butz and W-R Bias. [1993] The dehydrogenase assay with 
resazurin: Practical performance as a monitoring system and pH-dependent toxicity of 
phenolic compounds. Ecotoxicology Environmental Safety 25:79-89. 
 
IN VITRO TOXICOLOGY ASSAY KIT 
Resazurin Based 
Stock No. TOX-8 
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APPENDIX L 
 
Mice datasheet [105]  
 
Mice datasheet 
Strain Name: BALB/cJ 
Stock Number: 000651  
Availability: Level 1 
 
 
      Cell Line: BALB/cJ-PRX-BALB/cJ #9 mES cells 
      Cell Line: BALB/cJ-line I mES cells 
 
Common 
Names: 
C      
 
 
 
BALB/cJ is a commonly used inbred. Key traits include a resistance to experimental 
autoimmune encephalomyelitis (EAE), and a susceptibility to developing the 
demyelinating disease upon infection with Theiler's murine encephalomyelitis virus. 
The BALB/cJ substrain is susceptible to Listeria, all species of Leishmania, and 
several species of Trypanosoma, but is resistant to experimental allergic orchitis 
(EAO).  
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Strain Information 
Type Inbred Strain;  
Mating System 
Sibling x Sibling         (Female 
x Male)   01-MAR-06 
Breeding 
Considerations 
This strain is a challenging 
breeder.  
Species laboratory mouse 
H2 Haplotype D 
Generation F230 (02-JAN-10) 
 
 
 
Appearance 
albino 
Related Genotype: A/A Tyrp1b/Tyrp1b Tyrc/Tyrc  
Description 
BALB/c mice are particularly well known for the production of plasmacytomas 
following injection with mineral oil forming the basis for the production of monoclonal 
antibodies. Although not all BALB/c substrains have been examined for plasmacytoma 
induction, substrains derived from the Andervont (An) lineage (which includes 
BALB/cByJ) typically are susceptible, while those descended from BALB/cJ are 
resistant (see: Potter M ,1985). Mammary tumor incidence is normally low but infection 
with mammary tumor virus by fostering to MMTV+ C3H mice dramatically increases 
tumor number and age of onset. BALB/c mice develop other cancers later in life 
including reticular neoplasms, primary lung tumors, and renal tumors. Rare spontaneous 
myoepitheliomas arising from myoepithelial cells of various exocrine glands have been 
observed in both BALB/cJ and BALB/cByJ substrains. 
White et al. reported a variation in thioglycolate medium-induced peritoneal leukocyte 
recruitment in 4 analyzed strains. The response of total leukocyte recruitment, from 
greatest to least, was C57BL/6J>BALB/c>CD1>129X1/SvJ. Variations were also found 
in the timeline of response and cell types most impacted.  
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Dorso-ventral vaginal septa is observed in some BALB/cJ females, and may contribute 
to non-productive females in this strain. (Cunliffe-Beamer T, Lab Anim Sci, 1976)  
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APPENDIX M 
 
General Information about the 4T1 Cells [149] 
 
ATCC® Number: CRL-2539™     
Designations:  
4T1 
 
  
Depositors:   BA Pulaski  
Biosafety 
Level: 
1  
Shipped:  frozen  
Medium & 
Serum:  
See Propagation  
Growth 
Properties: 
adherent 
Organism: Mus musculus deposited as mouse  
Morphology: 
epithelial 
 
 
Source: 
Organ: mammary gland  
Strain: BALB/cfC3H  
Disease: tumor 
Permits/Forms: 
In addition to the MTA mentioned above, other ATCC and/or 
regulatory permits may be required for the transfer of this ATCC 
material. Anyone purchasing ATCC material is ultimately responsible 
for obtaining the permits. Please click here for information regarding 
the specific requirements for shipment to your location.  
Applications: 
4T1-induced tumors can be used as a post-operative model as well as 
a non-surgical model because the 4T1-induced tumor metastasizes 
spontaneously in both models with similar kinetics.  
Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as 
few as 1) can be detected in many distant site organs with better 
accuracy that most tumor models.  
When injected into BALB/c mice, 4T1 spontaneously produces 
highly metastatic tumors that can metastasize to the lung, liver, lymph 
nodes and brain while the primary tumor is growing in situ. 
  
Tumorigenic: Yes    
Comments: 
4T1 is a 6-thioguanine resistant cell line selected from the 410.4 
tumor without mutagen treatment.  
When injected into BALB/c mice, 4T1 spontaneously produces 
highly metastatic tumors that can metastasize to the lung, liver, lymph 
nodes and brain while the primary tumor is growing in situ.  
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The primary tumor does not have to be removed to induce metastatic 
growth.  
The tumor growth and metastatic spread of 4T1 cells in BALB/c mice 
very closely mimic human breast cancer. This tumor is an animal 
model for stage IV human breast cancer.  
4T1-induced tumors can be used as a post-operative model as well as 
a non-surgical model because the 4T1-induced tumor metastasizes 
spontaneously in both models with similar kinetics.  
Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as 
few as 1) can be detected in many distant site organs with better 
accuracy that most tumor models. There is no need to count nodules 
or weight target organs. 
Propagation:  
ATCC complete growth medium: The base medium for this cell 
line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. 
To make the complete growth medium, add the following components 
to the base medium: fetal bovine serum to a final concentration of 
10%. 
Temperature: 37.0°C  
Atmosphere: air, 95%; carbon dioxide (CO2), 5% 
  
Subculturing:  
Protocol: NOTE: the cells should not be allowed to become 
confluent, subculture at 80% of confluence. Remove medium, and 
rinse with 0.25% trypsin-0.53mM EDTA solution. Remove the 
solution and add an additional 1 to 2 ml of trypsin-EDTA solution. 
Allow the flask to sit at room temperature (or at 37.0°C) until the cells 
detach. Add fresh culture medium, aspirate and dispense into new 
culture flasks.  
Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:8 is 
recommended  
Medium Renewal: Every 2 to 3 days 
  
Preservation:  
Freeze medium: Complete growth medium 95%; DMSO, 5%  
Storage temperature: liquid nitrogen vapor temperature   
Related 
Products: 
Recommended medium (without the additional supplements or serum 
described under ATCC Medium):ATCC 30-2001 
recommended serum:ATCC 30-2020 
  
References: 
49687: Pulaski BA, et al. Immunotherapy with vaccines combining 
MHC class II/CD80+ tumor cells with interleukin-12 reduces 
established metastatic disease and stimulates immune effectors and 
monokine induced by interferon gamma. Cancer Immunol. 
Immunother. 49: 34-45, 2000. PubMed: 10782864 
49688: Pulaski BA, Ostrand-Rosenberg S. Reduction of established 
spontaneous mammary carcinoma metastases following 
immunotherapy with major histocompatibility complex class II and 
B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. 
PubMed: 9537252 
49689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus 
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enterotoxin B superantigen, major histocompatibility complex class II, 
and CD80 for immunotherapy of advanced spontaneous metastases in a 
clinically relevant postoperative mouse breast cancer model. Cancer 
Res. 60: 2710-2715, 2000. PubMed: 10825145 
49690: Aslakson CJ, Miller FR. Selective events in the metastatic 
process defined by analysis of the sequential dissemination of 
subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-
1405, 1992. PubMed: 1540948 
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APPENDIX N 
 
 
Formulation for RPMI-1640 Medium ATCC® 30-2001[153] 
 
ATCC 
 
Inorganic Salts (g/liter)  
 
Ca(NO3)2·4H2O   0.10000  
MgSO4 (anhydrous)   0.04884  
KCl     0.40000  
NaHCO3    1.50000  
NaCl     6.00000  
Na2HPO4 (anhydrous)  0.80000  
 
Amino Acids (g/liter)  
 
L-Arginine (free base)  0.20000  
L-Asparagine·H2O   0.05682  
L-Aspartic Acid   0.02000  
L-Cystine·2HCl   0.06520  
L-Glutamic Acid   0.02000  
L-Glutamine    0.30000  
Glycine    0.01000  
L-Histidine (free base)  0.01500  
Hydroxy-L-Proline   0.02000  
L-Isoleucine    0.05000  
L-Leucine    0.05000  
L-Lysine·HCl   0.04000  
L-Methionine    0.01500  
L-Phenylalanine   0.01500  
L-Proline    0.02000  
L-Serine    0.03000  
L-Threonine    0.02000  
L-Tryptophan    0.00500  
L-Tyrosine·2Na·2H2O  0.02883  
L-Valine   0.02000  
 
Vitamins (g/liter)  
 
D-Biotin    0.00020  
Choline Chloride   0.00300  
Folic Acid    0.00100  
myo-Inositol    0.03500  
Nicotinamide    0.00100  
p-Amino Benzoic Acid  0.00100  
D-Pantothenic Acid   0.00025  
(hemicalcium)  
Pyridoxine·HCl   0.00100  
Riboflavin    0.00020  
Thiamine·HCl   0.00100  
Vitamin B-12    0.000005  
 
Other (g/liter)  
 
D-Glucose    4.50000  
Glutathione (reduced)  0.00100  
HEPES    2.38300  
Phenol Red, Sodium Salt  0.00500  
Sodium Pyruvate   0.11000 
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APPENDIX O 
 
Cell Culturing 
A layer of a 0.1 % porcine gelatin was used as a substrate for growing 
endothelial cells. The sterile gelatin solution was added to the bottom of each flask 
using an appropriate volume that would create a thin layer. The gelatin was then left for 
10 minutes in the flask. After that time, the excess of gelatin was removed by aspirating 
it using a pipette connected to a vacuum system. The cells were kept in a controlled 
environment (37 ºC, 5 % CO2) in an incubator. The original cells that were received 
from the company were replicated according to the recommended procedure sent by the 
seller. When kept in a T-75 flask the cells will increase their number with time.  
After a certain stage, it is necessary to split the cells into more flasks in order to 
allow them to continue growing, without reaching full confluency. The confluency level 
defines the ratio between the surface area occupied by the cells and the surface area of 
the flask. When that ratio percentage is almost 100 %, the cells enter in a quasi-steady 
mode, where they basically stop or dramatically reduce their replication rates. The 
optimal level to split the cells used in our laboratory was between 75 to 85 %. Every 
time work was done with cells, the cell medium used was previously warmed in the 
incubator in order to have it ready at 37 ºC, minimizing the possibility of a temperature 
shock for the cells. The cell passage or subculturing is the designation for the transfer of 
the cells from one set of culture flasks to another. This cell transfer is required in order 
to increase the available surface area required by the cells to replicate more.  
Generally, human endothelial cells reach confluence after approximately 3 to 4 
days. To perform the cell passage, the medium was removed from the T-75 flasks using 
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Pasteur pipets that were connected to the vacuum system. The flasks were rinsed with 3 
mL of phosphate buffer saline (PBS) in order to wash the flask. This step is required 
and very important, because it allows for the complete removal of the F12K medium 
which has in its composition an accutase/trypsin inhibitor. The plate was gently shaken, 
and the solution was aspirated with the help of the vacuum system. Each T-75 flask 
received 3 mL of accutase/trypsin and was incubated for 10 minutes at 37 ºC. The new 
T-75 flasks were previously coated with gelatin. The gelatin (3 ml) was added to the 
flasks in order to cover the entire surface of the flask. The gelatin constitutes an 
adhesion support for the cells that will further attach to it and consequently to the 
surface of the plate. The gelatin was incubated in the flasks for 10 minutes at 37 ºC. 
After the incubation, the gelatin was removed and 9 mL of F12K medium were added to 
each T-75 flask. The cells that received the enzymes were visualized under an optical 
microscope after the 10 minutes incubation. Prior to visualization it is recommend to 
shake the flask in order to have the cells slightly moving. Under the microscope it is 
expected to see all of the cells floating in suspension. The majority must be detached 
from the surface at this point, and their morphology should look different with a 
rounded appearance, instead of the traditional elongated shape. If this does not happen, 
there was something that did not work properly and the assay must be restarted. If the 
majority of the cells are floating, it means that the action of the enzymes was successful. 
The T-75 flasks that had the lifted cells inside received 7 mL of warm F12K 
medium. The cells were mixed 3 or 4 times with the medium with the help of a pipettor. 
The medium was added to the cells in order to inhibit the action of the accutase/trypsin. 
That solution was then transferred to a 15 ml centrifuge tube. The tube was centrifuged 
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for 5 minutes at 1,100 rpm using a Mistral / MSE 3000 E centrifuge (Leicestershire, 
England). This allowed to collect all of the cells from the bottom of the tube. After 
centrifugation, 9 ml of the solution were carefully removed and 1 ml was left in the 
bottom of the tube. Eight ml of medium were added to the tube, and the solution was 
pipetted several times in order to resuspend all of the cells and allow for obtaining a 
homogeneous cell suspension. A failure on this step can result in transfer of unequal 
number of cells per flask. Assuming a 1:3 cell passage, each T-75 flask received 3 ml of 
the cells’ solution. Last, the cells were incubated at 37 ºC, 5 % CO2 in the incubator. 
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APPENDIX P 
Cell staining 
1. Grow the endothelial cells in the T-75 flasks under the appropriate conditions. 
2. When the cells are approximately 75-80 % confluent, passage them into the 2-
chamber slides. 
3. In order to have the cells adhering to the glass cover slides it is important to pre-
coat the surface with 300 µl of 0.1 % sterile pig gelatin for 10 minutes. After 10 
minutes, remove the excess of gelatin and let the chambers dry for 15 minutes 
with the lids off.  
4. Add 1,000 µl of endothelial cells to each well. Put the chamber in the incubator. 
5. Wait 24 h. 
6. Carefully remove the cell medium from the wells. 
7. Add 1 ml of the SWNT-FITC-Annexin V conjugate at a concentration of 6 
mg/L to the Petri dish. The conjugate must be diluted with cell medium and 2 
mM Ca2+. 
8. Incubate for 2 h in the incubator. 
9. Wash the wells 4x with cell medium and 2 mM Ca2+. 
10. Dilute the Cell Mask by placing 1.5 µl of the stock solution (5 mg/ml) in 1 ml of 
cell medium. 
11. Add 300 µl of the diluted Cell Mask to each well and incubate in the incubator 
for 30 minutes. 
12. Remove the staining solution. 
13. Wash 4x with cell medium and 2 mM Ca2+. 
14. Fix the cells with 0.25 % glutaraldehyde for 5 minutes at 37 ºC. 
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15. Wash 4x with cell medium and 2 mM Ca2+. 
16. Place a drop of Fluoro-gel on a microscope glass slide. 
17. Invert the glass cover slide and have the cells touching the gel.  
18. Check for fluorescence using the Fluorescence microscope. 
The emission and excitation wavelengths for CellMask are 649 and 666 nm, 
respectively. All of the dyes used for the staining are light-sensitive, and in order to 
preserve their fluorescence abilities, the exposure of them to the light was minimized. 
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APPENDIX Q 
 
In Vitro Binding Assay 
In order to perform the biotinylation, the lyophilized protein annexin V was 
reconstituted with 1 ml of buffer (80 mM sodium phosphate dibasic, 50 mM NaCl, pH 
7.4). The vial was then stirred for 30 minutes at 4 ºC. 1 mg of biotin (SureLINK 
Chromophoric Biotin, KPL, Inc., Gaithersburg, MD) was dissolved in 100 µl of 
anhydrous DMF immediately prior to use. Using a 40-fold excess of biotin for the 
conjugation, 88.67 µl of biotin (20 mg/ml) were added to the protein solution. The vial 
was then incubated at 4 ºC for 4 hours with gentle agitation. The unconjugated 
chromophoric biotin was removed by dialysis using a Slide-A-Lyzer dialysis cassette 
with a molecular weight cut-off of 3,500 Da. The buffer used was 1 liter of 1 X 
modification buffer (80 mM sodium phosphate dibasic, 50 mM NaCl, pH 7.4). The 
dialysis was performed for 20 h at 4 ºC for with a buffer replacement at 3 and 6 h from 
the beginning of the dialysis. The biotinylated protein was placed in aliquots and stored 
in a nitrogen tank.  
The dissociation constant was determined in vitro using 70-80 % confluent 
human endothelial cells cultured in 24-well plates. In order to promote the 
externalization of the PS molecules on the cells, 1 mM H2O2 was added to the cells and 
incubated for 1 h at 37 ºC, 5 % CO2. For each concentration of annexin V studied, three 
data points were obtained and averaged. Prior to the protein incubation, the cells were 
fixed with 100 µl/well of PBS buffer containing 0.25 % glutaraldehyde. The excess of 
aldehyde groups were quenched by incubating with 100 µl/well of 50 mM NH4Cl 
diluted in PBS buffer for 5 minutes at room temperature. The biotinylated annexin V 
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was diluted to several concentrations, and it was incubated for 2 h at 37 ºC, 5 % CO2 in 
the incubator. BSA (0.5 %) diluted in PBS buffer was used to dilute the protein. For the 
specific binding, 2 mM CaCl was added to the PBS. For the non-specific binding, the 
calcium was depleted from the cells by adding 5 mM EDTA. Following the 2 h 
incubation, the wells were washed four times with 300 µl of 0.5 % BSA diluted in PBS 
buffer. Streptavidin-HRP (300 µl, 2 µg/ml) were added and incubated for 1 h at room 
temperature. Further wash was done four times with 300 µl of PBS buffer. O-
phenylenediamine (300 µl, OPD) was then added to each well and incubated for 30 
minutes at room temperature in the dark to minimize OPD color change. The 
absorbance was measured at 450 nm using the microtiter plate reader. A Forma 
Scientific incubator was also for the cell incubation (Forma Scientific, Inc., Marietta, 
OH). 
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APPENDIX R 
 
Anesthetic Procedure 
In order to anesthetize the animals, the respective cage was open from the top 
and without removing the top lid completely; the mouse was captured by grabbing its 
tail. The animal was then placed on top of the blue mat, allowing it to grab it with its 
front legs. The animal was then grabbed by the back of his head, and its tail was also 
immobilized using the left hand. This allowed for the intraperitoneal (i. p.) injection of 
the anesthetic. The i. p. injections were done by placing the needle a few millimeters 
into the body of the organism in a specific region. In order to find that region located at 
the lower part of the animal’s abdomen, it is important to visualize two imaginary lines 
that will intersect. The first line can be visualized along the midsagittal plane (a vertical 
plane that goes through the midline of the body) of the body, while the second line will 
be oriented using the transverse plane (plane that passes horizontally across the body 
and perpendicular to the midsagittal plane). The intersection of both lines on the 
abdomen region and just above the lower members gives us an imaginary point, which 
will be used as an orientation mark. From this position, it is measured around 5 mm in 
diagonal towards the left or right bottom quadrant (Figure Q.1).  
 
Figure R.1: Illustration showing the method used for the i.p. injections [154]. 
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This will determine the point of injection. Changes to this location are not encouraged 
and can actually be hazardous and compromise vital organs. Also, the depth of 
penetration of the needle should not be too deep.  
After injecting the entire volume of the anesthetic, the mouse was placed back in 
the cage allowing some time for the mouse to become completely immobilized. 
Generally, this occurs between 5 to 10 minutes after the i. p. injection. Multiple 
injections for several animals can be done sequentially in order to maximize the number 
of animals being immobilized during the entire session. 
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APPENDIX S 
 
Tail Vein Injections 
For the tail vein injections, 30 gauge needles and syringes were used. In order to 
facilitate this process, the tail of each mouse was placed in a 2 L beaker filled with 
warm water for 30 seconds. This step allows for the dilatation of the tail veins, making 
it easier to inject into the veins. Each mouse has 2 tail veins – left and right veins 
(Figure R.1).  
 
Figure S.1: Mouse tail anatomy [155]. 
 
After dilating the veins, the mouse was placed on the bench, the tail was cleaned 
and the solution was injected. The injection used 150 µl of the solution per animal. In 
case of failure to inject the solution into the vein, an accumulation of the solution was 
visible under the skin. When that happened, the injection on that particular site was 
aborted, and a different spot was chosen to inject the solution. It is not recommended to 
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attempt more than three times per vein, in order to maintain the integrity of the vein. 
When the injections are successful it is possible to see the solution entering the vein and 
being transported into the abdomen. It is also important to mention that all of the safety 
protocols were followed and for each animal, a different set of needles and syringes 
were used in order to avoid any contamination or disease propagation between the 
individuals. If bleeding occurred after injecting into the tail vein, pressure was applied 
on that spot for some time until the bleeding completely stopped. After injection, the 
animal was placed in the cage again. After a certain amount of time (which varied 
between individuals but never exceeded 1 hour), the animals were fully awake and 
restored the march completely. 
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APPENDIX T 
 
Biodistribution study 
 
Figure T.1: Standard curve as a function of the G band peak intensity at 1,590 cm-1 vs. 
nanotube concentration. The SWNTs were suspended in lysis buffer (1% SDS, 1% 
Triton-X 100, 10 mM DTT, 40 mM tris-acetate-EDTA buffer). The samples were 
placed in a Ge metallic disk and allowed to dry. The signal was acquired using 64 scans. 
